Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,100 | 2021-05-01 00:00:00 UTC | Better Buy for 2021: AbbVie or Merck? | ABBV | https://www.nasdaq.com/articles/better-buy-for-2021%3A-abbvie-or-merck-2021-05-01 | null | null | AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) currently boast the No. 1 and No. 2 best-selling drugs on the market. AbbVie's Humira, which is used to treat Crohn's disease, just grossed $20 billion in sales in 2020, while Merck's No. 2, Keytruda, did $14.38 billion in sales. With patent cliffs looming for both drugs in the... | We were really able to see AbbVie's diversification, as the strength in the company's aesthetics business helped offset the mounting pressure on its flagship drug Humira. AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) currently boast the No. AbbVie's Humira, which is used to treat Crohn's disease, just grossed $20 billion i... | AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) currently boast the No. AbbVie's Humira, which is used to treat Crohn's disease, just grossed $20 billion in sales in 2020, while Merck's No. The case for AbbVie In 2013, AbbVie was spun off by its parent company, Abbott Labs, in a decision to separate two fundamentally differe... | AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) currently boast the No. AbbVie's Humira, which is used to treat Crohn's disease, just grossed $20 billion in sales in 2020, while Merck's No. The case for AbbVie In 2013, AbbVie was spun off by its parent company, Abbott Labs, in a decision to separate two fundamentally differe... | AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) currently boast the No. AbbVie's Humira, which is used to treat Crohn's disease, just grossed $20 billion in sales in 2020, while Merck's No. The case for AbbVie In 2013, AbbVie was spun off by its parent company, Abbott Labs, in a decision to separate two fundamentally differe... |
24,101 | 2021-04-30 00:00:00 UTC | 7 Value Stocks You Want In Your Life | ABBV | https://www.nasdaq.com/articles/7-value-stocks-you-want-in-your-life-2021-04-30 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Theoretically, we really should have seen a renaissance in value stocks during the impact of the novel coronavirus pandemic. With an unprecedented crisis rippling throughout the international community, the global equity markets initially tumbled on the mas... | Nintendo (OTCMKTS:NTDOY) NRG Energy (NYSE:NRG) AbbVie (NYSE:ABBV) Altria Group (NYSE:MO) The Geo Group (NYSE:GEO) Sunoco (NYSE:SUN) Anheuser Busch (NYSE:BUD) Value Stocks to Buy: Nintendo (NTDOY) NTDOY) sits in front of a bright pink background." Value Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone... | Nintendo (OTCMKTS:NTDOY) NRG Energy (NYSE:NRG) AbbVie (NYSE:ABBV) Altria Group (NYSE:MO) The Geo Group (NYSE:GEO) Sunoco (NYSE:SUN) Anheuser Busch (NYSE:BUD) Value Stocks to Buy: Nintendo (NTDOY) NTDOY) sits in front of a bright pink background." Value Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone... | Nintendo (OTCMKTS:NTDOY) NRG Energy (NYSE:NRG) AbbVie (NYSE:ABBV) Altria Group (NYSE:MO) The Geo Group (NYSE:GEO) Sunoco (NYSE:SUN) Anheuser Busch (NYSE:BUD) Value Stocks to Buy: Nintendo (NTDOY) NTDOY) sits in front of a bright pink background." Value Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone... | Therefore, ABBV stock makes sense on the fundamentals shifting favorably toward its underlying business. Nintendo (OTCMKTS:NTDOY) NRG Energy (NYSE:NRG) AbbVie (NYSE:ABBV) Altria Group (NYSE:MO) The Geo Group (NYSE:GEO) Sunoco (NYSE:SUN) Anheuser Busch (NYSE:BUD) Value Stocks to Buy: Nintendo (NTDOY) NTDOY) sits in fron... |
24,102 | 2021-04-30 00:00:00 UTC | AbbVie Rises on Q1 Beats, Raised EPS Guidance | ABBV | https://www.nasdaq.com/articles/abbvie-rises-on-q1-beats-raised-eps-guidance-2021-04-30 | null | null | AbbVie (NYSE: ABBV) stock was defying gravity on Friday, rising on the back of an encouraging first-quarter earnings report published this morning.
For the quarter, the veteran pharmaceutical company booked non-GAAP (adjusted) net revenue of just over $12.94 billion, a robust 50% over the Q1 2020 result. Net profit als... | AbbVie (NYSE: ABBV) stock was defying gravity on Friday, rising on the back of an encouraging first-quarter earnings report published this morning. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! On a non-GAAP per-share basis, AbbV... | AbbVie (NYSE: ABBV) stock was defying gravity on Friday, rising on the back of an encouraging first-quarter earnings report published this morning. On a non-GAAP per-share basis, AbbVie netted $2.95, up from the year-ago figure of $2.42. AbbVie enjoyed increased sales in both its overall therapeutic categories and with... | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. AbbVie (NYSE: ABBV) stock was defying gravity on Friday, rising on the back of an encouraging first-quarter earnings report published this morning. On a non-GAAP per-share basis, AbbVie netted $2.9... | AbbVie (NYSE: ABBV) stock was defying gravity on Friday, rising on the back of an encouraging first-quarter earnings report published this morning. On a non-GAAP per-share basis, AbbVie netted $2.95, up from the year-ago figure of $2.42. AbbVie enjoyed increased sales in both its overall therapeutic categories and with... |
24,103 | 2021-04-30 00:00:00 UTC | US STOCKS-Wall Street ends lower, weighed down by Apple | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-street-ends-lower-weighed-down-by-apple-2021-04-30-0 | null | null | By Noel Randewich and Shivani Kumaresan
April 30 (Reuters) - Wall Street ended lower on Friday, with Amazon, Apple, Alphabet and other tech-related companies weighing on the S&P 500 and Nasdaq despite recent strong quarterly earnings reports.
A day after the S&P 500 closed at a record high, Apple AAPL.O, Google-parent ... | AbbVie Inc ABBV.N rose 0.5% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Amazon, Apple, Alphabet and other tech-related... | AbbVie Inc ABBV.N rose 0.5% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Amazon, Apple, Alphabet and other tech-related... | AbbVie Inc ABBV.N rose 0.5% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Amazon, Apple, Alphabet and other tech-related... | AbbVie Inc ABBV.N rose 0.5% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Amazon, Apple, Alphabet and other tech-related... |
24,104 | 2021-04-30 00:00:00 UTC | US STOCKS-Wall Street ends lower, weighed down by Apple | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-street-ends-lower-weighed-down-by-apple-2021-04-30 | null | null | By Noel Randewich and Shivani Kumaresan
April 30 (Reuters) - Wall Street ended lower on Friday, with Apple, Alphabet and other tech-related companies weighing on the S&P 500 and Nasdaq despite recent strong quarterly earnings reports.
A day after the S&P 500 closed at a record high, Apple AAPL.O, Google-parent Alphabet... | AbbVie Inc ABBV.Nrose after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Apple, Alphabet and other tech-related companies wei... | AbbVie Inc ABBV.Nrose after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Apple, Alphabet and other tech-related companies wei... | AbbVie Inc ABBV.Nrose after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Apple, Alphabet and other tech-related companies wei... | AbbVie Inc ABBV.Nrose after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street ended lower on Friday, with Apple, Alphabet and other tech-related companies wei... |
24,105 | 2021-04-30 00:00:00 UTC | US STOCKS-Apple and Alphabet pull Wall Street lower | ABBV | https://www.nasdaq.com/articles/us-stocks-apple-and-alphabet-pull-wall-street-lower-2021-04-30 | null | null | By Noel Randewich and Shivani Kumaresan
April 30 (Reuters) - Wall Street dropped on Friday, with Apple, Alphabet and other tech-related companies dipping despite recent strong quarterly earnings reports.
A day after the S&P 500 closed at a record high, Apple AAPL.O, Google-parent Alphabet GOOGL.O and Facebook FB.O each... | AbbVie Inc ABBV.N rose 0.6% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street dropped on Friday, with Apple, Alphabet and other tech-related companies d... | AbbVie Inc ABBV.N rose 0.6% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street dropped on Friday, with Apple, Alphabet and other tech-related companies d... | AbbVie Inc ABBV.N rose 0.6% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street dropped on Friday, with Apple, Alphabet and other tech-related companies d... | AbbVie Inc ABBV.N rose 0.6% after it reported strong results and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Noel Randewich and Shivani Kumaresan April 30 (Reuters) - Wall Street dropped on Friday, with Apple, Alphabet and other tech-related companies d... |
24,106 | 2021-04-30 00:00:00 UTC | AbbVie (ABBV) Q1 2021 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q1-2021-earnings-call-transcript-2021-04-30 | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q1 2021 Earnings Call
Apr 30, 2021, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie first-quarter 2021earnings conference call [Operator instru... | AbbVie (NYSE: ABBV) Q1 2021 Earnings Call Apr 30, 2021, 9:00 a.m. Welcome to the AbbVie first-quarter 2021earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president of investor relations. AbbVie cautions that these forward-looking statements are subject to risks and unce... | And we expect more than a half a dozen new product or indication launches in 2022, including navitoclax for myelofibrosis, ABBV-951 for advanced Parkinson's disease, Skyrizi for psoriatic arthritis and Crohn's disease, Rinvoq for ulcerative colitis, Vraylar for major depressive disorder, and initial indications for Imb... | Operator [Operator signoff] Duration: 78 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vi... | Operator [Operator signoff] Duration: 78 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vi... |
24,107 | 2021-04-30 00:00:00 UTC | Notable Friday Option Activity: BZH, AXP, ABBV | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-bzh-axp-abbv-2021-04-30 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Beazer Homes USA, Inc. (Symbol: BZH), where a total of 1,585 contracts have traded so far, representing approximately 158,500 underlying shares. That amounts to about 47.4% of BZH's average daily trading volume ... | Especially high volume was seen for the $112 strike call option expiring April 30, 2021, with 3,836 contracts trading so far today, representing approximately 383,600 underlying shares of ABBV. Below is a chart showing AXP's trailing twelve month trading history, with the $150 strike highlighted in orange: And AbbVie I... | Below is a chart showing AXP's trailing twelve month trading history, with the $150 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,408 contracts, representing approximately 2.8 million underlying shares or approximately 45.8% of ABBV's average daily trading volume over the ... | Below is a chart showing AXP's trailing twelve month trading history, with the $150 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,408 contracts, representing approximately 2.8 million underlying shares or approximately 45.8% of ABBV's average daily trading volume over the ... | Below is a chart showing AXP's trailing twelve month trading history, with the $150 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,408 contracts, representing approximately 2.8 million underlying shares or approximately 45.8% of ABBV's average daily trading volume over the ... |
24,108 | 2021-04-30 00:00:00 UTC | Health Care Sector Update for 04/30/2021: AZN, MESO, ABBV, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-04-30-2021%3A-azn-meso-abbv-xlv-ibb-2021-04-30 | null | null | Health care stocks were declining in Friday's premarket trading. The Health Care SPDR (XLV) was down 0.3% and the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower recently.
AstraZeneca (AZN) was climbing past 3% as it reported Q1 core earnings of $1.63 per share, up from $1.05 a year ago. The consensus of analys... | AbbVie (ABBV) was up more than 1% as it posted Q1 adjusted earnings of $2.95 per share, up from $2.42 per share a year earlier. The Health Care SPDR (XLV) was down 0.3% and the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower recently. AstraZeneca (AZN) was climbing past 3% as it reported Q1 core earnings of $1.... | AbbVie (ABBV) was up more than 1% as it posted Q1 adjusted earnings of $2.95 per share, up from $2.42 per share a year earlier. The consensus of analysts polled by Capital IQ was $1.46. Analysts polled by Capital IQ projected adjusted EPS of $2.83. | AbbVie (ABBV) was up more than 1% as it posted Q1 adjusted earnings of $2.95 per share, up from $2.42 per share a year earlier. The Health Care SPDR (XLV) was down 0.3% and the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower recently. The views and opinions expressed herein are the views and opinions of the aut... | AbbVie (ABBV) was up more than 1% as it posted Q1 adjusted earnings of $2.95 per share, up from $2.42 per share a year earlier. Health care stocks were declining in Friday's premarket trading. The Health Care SPDR (XLV) was down 0.3% and the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower recently. |
24,109 | 2021-04-30 00:00:00 UTC | How AbbVie Beat Expectations Again in Q1 | ABBV | https://www.nasdaq.com/articles/how-abbvie-beat-expectations-again-in-q1-2021-04-30 | null | null | Few stocks offer the combination of growth, value, and income that AbbVie (NYSE: ABBV) does. However, investors have been concerned about just how long the drugmaker will be able to continue delivering solid growth.
AbbVie announced its first-quarter results before the market opened on Friday. And the growth streak con... | Behind the numbers As has been the case since AbbVie began operations as an independent entity in 2013, Humira took center stage in the company's quarterly update. The Food and Drug Administration pushed back the review period by three months for AbbVie's regulatory applications for Rinvoq in treating atopic dermatitis... | Few stocks offer the combination of growth, value, and income that AbbVie (NYSE: ABBV) does. AbbVie announced its first-quarter results before the market opened on Friday. Here are the highlights from AbbVie's first-quarter update. | AbbVie recorded adjusted earnings of $2.95 per share, up 22% year over year. AbbVie recorded U.S. sales of $999 million plus $269 million for its share of profits on international sales of the drug by Johnson & Johnson. (Since AbbVie's acquisition of Allergan didn't close until May 2020, this refers to what the growth ... | AbbVie recorded adjusted earnings of $2.95 per share, up 22% year over year. Few stocks offer the combination of growth, value, and income that AbbVie (NYSE: ABBV) does. AbbVie announced its first-quarter results before the market opened on Friday. |
24,110 | 2021-04-30 00:00:00 UTC | AbbVie raises full-year profit forecast as Humira fuels quarterly sales | ABBV | https://www.nasdaq.com/articles/abbvie-raises-full-year-profit-forecast-as-humira-fuels-quarterly-sales-2021-04-30 | null | null | Adds profit estimates, background on Humira, Botox, and share movement
April 30 (Reuters) - AbbVie Inc ABBV.N on Friday beat estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States where it is yet to face competition from ... | AbbVie's beat-and-raise quarter come after several rival drugmakers such as Eli Lilly LLY.N, Merck & Co Inc MRK.N and Bristol Myers Squibb BMY.N missed estimates for first-quarter earnings. Shares of the North Chicago, Illinois-based company climbed 2.1% in premarket trading after AbbVie's revenue was also lifted by re... | Adds profit estimates, background on Humira, Botox, and share movement April 30 (Reuters) - AbbVie Inc ABBV.N on Friday beat estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States where it is yet to face competition from ... | Adds profit estimates, background on Humira, Botox, and share movement April 30 (Reuters) - AbbVie Inc ABBV.N on Friday beat estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States where it is yet to face competition from ... | Adds profit estimates, background on Humira, Botox, and share movement April 30 (Reuters) - AbbVie Inc ABBV.N on Friday beat estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States where it is yet to face competition from ... |
24,111 | 2021-04-30 00:00:00 UTC | Increases to CEO Compensation Might Be Put On Hold For Now at AbbVie Inc. (NYSE:ABBV) | ABBV | https://www.nasdaq.com/articles/increases-to-ceo-compensation-might-be-put-on-hold-for-now-at-abbvie-inc.-nyse%3Aabbv-2021 | null | null | Performance at AbbVie Inc. (NYSE:ABBV) has been reasonably good and CEO Rick Gonzalez has done a decent job of steering the company in the right direction. In light of this performance, CEO compensation will probably not be the main focus for shareholders as they go into the AGM on 07 May 2021. However, some shareholde... | Performance at AbbVie Inc. (NYSE:ABBV) has been reasonably good and CEO Rick Gonzalez has done a decent job of steering the company in the right direction. At the time of writing, our data shows that AbbVie Inc. has a market capitalization of US$196b, and reported total annual CEO compensation of US$24m for the year to... | Performance at AbbVie Inc. (NYSE:ABBV) has been reasonably good and CEO Rick Gonzalez has done a decent job of steering the company in the right direction. At the time of writing, our data shows that AbbVie Inc. has a market capitalization of US$196b, and reported total annual CEO compensation of US$24m for the year to... | Performance at AbbVie Inc. (NYSE:ABBV) has been reasonably good and CEO Rick Gonzalez has done a decent job of steering the company in the right direction. NYSE:ABBV CEO Compensation April 30th 2021 A Look at AbbVie Inc.'s Growth Numbers Over the last three years, AbbVie Inc. has shrunk its earnings per share by 6.2% p... | AbbVie Inc. has generated a total shareholder return of 29% over three years, so most shareholders would be reasonably content. Performance at AbbVie Inc. (NYSE:ABBV) has been reasonably good and CEO Rick Gonzalez has done a decent job of steering the company in the right direction. At the time of writing, our data sho... |
24,112 | 2021-04-30 00:00:00 UTC | 3 Warren Buffett Stocks Worth Buying Now | ABBV | https://www.nasdaq.com/articles/3-warren-buffett-stocks-worth-buying-now-2021-04-30 | null | null | For some investors there's a certain thrill in finding your own stocks to buy. For other investors, punting this duty to a proven expert is not only smart, but a time-saver too. And if you're part of this latter group, Warren Buffett's Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) is as good of a place as any (if not ... | AbbVie Those who know AbbVie (NYSE: ABBV) well may be surprised to learn it was another major addition to the Berkshire portfolio just late last year. Biosimilar alternatives are expected to become widely available by 2023, posing a threat to a huge chunk of AbbVie's business. While there's no drug that will single-han... | AbbVie Those who know AbbVie (NYSE: ABBV) well may be surprised to learn it was another major addition to the Berkshire portfolio just late last year. Biosimilar alternatives are expected to become widely available by 2023, posing a threat to a huge chunk of AbbVie's business. While there's no drug that will single-han... | Ultimately, though -- like Verizon and AbbVie -- Bank of New York Mellon's chief appeal to Berkshire Hathaway is its resilient business model and its subsequently resilient dividend. AbbVie Those who know AbbVie (NYSE: ABBV) well may be surprised to learn it was another major addition to the Berkshire portfolio just la... | AbbVie Those who know AbbVie (NYSE: ABBV) well may be surprised to learn it was another major addition to the Berkshire portfolio just late last year. Biosimilar alternatives are expected to become widely available by 2023, posing a threat to a huge chunk of AbbVie's business. While there's no drug that will single-han... |
24,113 | 2021-04-30 00:00:00 UTC | AbbVie Q1 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q1-adjusted-earnings-beat-estimates-2021-04-30 | null | null | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV):
-Earnings: $3.55 billion in Q1 vs. $3.01 billion in the same period last year. -EPS: $1.99 in Q1 vs. $2.02 in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.27 billion or $2.95 per share for the period. -Analysts proj... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $3.55 billion in Q1 vs. $3.01 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.27 billion or $2.95 per share for the period. -Guidance: Full year EPS guidance: $12.37 to $12.57 The views and opinio... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $3.55 billion in Q1 vs. $3.01 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.27 billion or $2.95 per share for the period. -Analysts projected $2.83 per share -Revenue: $13.01 billion in Q1 vs. $... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $3.55 billion in Q1 vs. $3.01 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.27 billion or $2.95 per share for the period. -Analysts projected $2.83 per share -Revenue: $13.01 billion in Q1 vs. $... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $3.55 billion in Q1 vs. $3.01 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.27 billion or $2.95 per share for the period. -Guidance: Full year EPS guidance: $12.37 to $12.57 The views and opinio... |
24,114 | 2021-04-30 00:00:00 UTC | US STOCKS-Wall Street drifts lower; S&P 500 on track for third straight month of gains | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-street-drifts-lower-sp-500-on-track-for-third-straight-month-of-gains-2021 | null | null | By Shivani Kumaresan
April 30 (Reuters) - Wall Street's three main indexes fell on Friday as investors hit pause after a barrage of strong quarterly earnings and upbeat economic data put the benchmark S&P 500 index on track for a third straight month of gains following a record run.
The Nasdaq .IXIC is also positioned ... | AbbVie Inc ABBV.N rose 0.2% after beating estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. The Nasdaq .IXIC is also positioned for six consecutive months of gains, boosted by a rally in shares of big technology com... | AbbVie Inc ABBV.N rose 0.2% after beating estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Shivani Kumaresan April 30 (Reuters) - Wall Street's three main indexes fell on Friday as investors hit pause after a ba... | AbbVie Inc ABBV.N rose 0.2% after beating estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Shivani Kumaresan April 30 (Reuters) - Wall Street's three main indexes fell on Friday as investors hit pause after a ba... | AbbVie Inc ABBV.N rose 0.2% after beating estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States. By Shivani Kumaresan April 30 (Reuters) - Wall Street's three main indexes fell on Friday as investors hit pause after a ba... |
24,115 | 2021-04-29 00:00:00 UTC | Pre-Market Earnings Report for April 30, 2021 : XOM, CVX, ABBV, AZN, CHTR, ITW, CL, AON, JCI, LHX, LYB, PSX | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-april-30-2021-%3A-xom-cvx-abbv-azn-chtr-itw-cl-aon-jci-lhx | null | null | The following companies are expected to report earnings prior to market open on 04/30/2021. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM) is reporting for the quarter ending March 31, 2021. The oil company's consensus earnings per share forecast from the 8 ana... | AbbVie Inc. (ABBV) is reporting for the quarter ending March 31, 2021. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.95 vs. an industry ratio of 14.20. | AbbVie Inc. (ABBV) is reporting for the quarter ending March 31, 2021. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.95 vs. an industry ratio of 14.20. | AbbVie Inc. (ABBV) is reporting for the quarter ending March 31, 2021. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.95 vs. an industry ratio of 14.20. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV) is reporting for the quarter ending March 31, 2021. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.95 vs. an industry ratio of 14.20. |
24,116 | 2021-04-29 00:00:00 UTC | June 11th Options Now Available For AbbVie | ABBV | https://www.nasdaq.com/articles/june-11th-options-now-available-for-abbvie-2021-04-29 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the June 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 11th contracts and identified one put and one call contract of particular interest.
The put contrac... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $110.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $115.00 strike price has a current bid of $1.77. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 11th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $115.00 strike highlighted in red: Consideri... |
24,117 | 2021-04-29 00:00:00 UTC | 2 Undervalued Pharmaceutical Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/2-undervalued-pharmaceutical-stocks-to-buy-now-2021-04-29 | null | null | Some investors love their dividends. Lucky for them, there are a lot of great companies that can afford to pay their shareholders cash every quarter. Pharma giants AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) boast high and sustainable dividend yields that are great for investors who want to see those dividends ... | AbbVie's continued sales from drugs like best-selling Humira, Skyrizi, and Rinvoq, suggest that it could grow its dividend well into the future. Pharma giants AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) boast high and sustainable dividend yields that are great for investors who want to see those dividends hit t... | Pharma giants AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) boast high and sustainable dividend yields that are great for investors who want to see those dividends hit their account every three months. Growing dividends AbbVie has rewarded shareholders tremendously over the past few years through dividend increas... | Pharma giants AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) boast high and sustainable dividend yields that are great for investors who want to see those dividends hit their account every three months. Growing dividends AbbVie has rewarded shareholders tremendously over the past few years through dividend increas... | Despite growing earnings and raising its dividend over the past few years, AbbVie is 9% below its 2018 high of $123. Growing dividends AbbVie has rewarded shareholders tremendously over the past few years through dividend increases. Pharma giants AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) boast high and sustai... |
24,118 | 2021-04-28 00:00:00 UTC | Best Stocks To Invest In 2021? 4 Dividend Stocks To Watch | ABBV | https://www.nasdaq.com/articles/best-stocks-to-invest-in-2021-4-dividend-stocks-to-watch-2021-04-28 | null | null | Are These The Best Dividend Stocks To Buy Right Now?
If there’s one thing investors want in the stock market, it’s high yield dividend stocks that can produce a steady income stream that can sustain them throughout their life. When you think about dividend stocks, what comes to mind? Most likely, you’re thinking of som... | Top Dividend Yield Stocks To Watch Now Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corp. (NYSE: CVX) Exxon Mobil Corp. (NYSE: XOM) Realty Income It’s one thing to get paid a dividend, but getting paid every month is even better, particularly if they have a high yield. [Read More] 4 Consumer Discretionary S... | Top Dividend Yield Stocks To Watch Now Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corp. (NYSE: CVX) Exxon Mobil Corp. (NYSE: XOM) Realty Income It’s one thing to get paid a dividend, but getting paid every month is even better, particularly if they have a high yield. [Read More] 4 Consumer Discretionary S... | Top Dividend Yield Stocks To Watch Now Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corp. (NYSE: CVX) Exxon Mobil Corp. (NYSE: XOM) Realty Income It’s one thing to get paid a dividend, but getting paid every month is even better, particularly if they have a high yield. [Read More] 4 Consumer Discretionary S... | Top Dividend Yield Stocks To Watch Now Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corp. (NYSE: CVX) Exxon Mobil Corp. (NYSE: XOM) Realty Income It’s one thing to get paid a dividend, but getting paid every month is even better, particularly if they have a high yield. [Read More] 4 Consumer Discretionary S... |
24,119 | 2021-04-28 00:00:00 UTC | Is AbbVie a Buy Before Its Earnings Report Friday? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-buy-before-its-earnings-report-friday-2021-04-28 | null | null | For savvy investors, trading stocks around the earnings cycle is a risky but common tactic. Especially for companies with highly reliable revenue, buying in before a major earnings report can often secure you a small bargain. In that vein, the pharma juggernaut AbbVie (NYSE: ABBV) reports its first-quarter earnings for... | In that vein, the pharma juggernaut AbbVie (NYSE: ABBV) reports its first-quarter earnings for 2021 on Friday, and investors will get new insights on how its pivot away from its blockbuster arthritis drug Humira is progressing. Despite the prospect for good news stemming from hot sales in its immunology and oncology po... | Oncology and immunology sales probably keep booming The strongest argument in favor of buying AbbVie before the earnings report is that revenue growth from its immunology drugs like Skyrizi and Rinvoq will be robust for the foreseeable future. In that vein, the pharma juggernaut AbbVie (NYSE: ABBV) reports its first-qu... | Oncology and immunology sales probably keep booming The strongest argument in favor of buying AbbVie before the earnings report is that revenue growth from its immunology drugs like Skyrizi and Rinvoq will be robust for the foreseeable future. The more rapidly that biosimilars eat Humira's market share, the less time A... | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! In that vein, the pharma juggernaut AbbVie (NYSE: ABBV) reports its first-quarter earnings for 2021 on Friday, and investors will get new insights on how its pivot away from its block... |
24,120 | 2021-04-28 00:00:00 UTC | 7 Pharmaceutical Stocks With Dividends in Hand | ABBV | https://www.nasdaq.com/articles/7-pharmaceutical-stocks-with-dividends-in-hand-2021-04-28 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
News of game-changing drugs, treatments and vaccines may dominate the headlines when it comes to pharmaceutical stocks. But, taking a gamble with high-risk, high-possible return biotech stocks isn’t the only way to approach this sector. There are less risky... | Consider these seven compelling opportunities: AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck & Co. (NYSE:MRK) Novartis (NYSE:NVS) Pharmaceutical Stocks: AbbVie (ABBV) Yielding 4.97%, ABBV stock is an intriguing opportunity ... | Consider these seven compelling opportunities: AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck & Co. (NYSE:MRK) Novartis (NYSE:NVS) Pharmaceutical Stocks: AbbVie (ABBV) Yielding 4.97%, ABBV stock is an intriguing opportunity ... | Consider these seven compelling opportunities: AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck & Co. (NYSE:MRK) Novartis (NYSE:NVS) Pharmaceutical Stocks: AbbVie (ABBV) Yielding 4.97%, ABBV stock is an intriguing opportunity ... | Consider these seven compelling opportunities: AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck & Co. (NYSE:MRK) Novartis (NYSE:NVS) Pharmaceutical Stocks: AbbVie (ABBV) Yielding 4.97%, ABBV stock is an intriguing opportunity ... |
24,121 | 2021-04-27 00:00:00 UTC | Does This First-in-Class Acquisition Make Amgen a Buy? | ABBV | https://www.nasdaq.com/articles/does-this-first-in-class-acquisition-make-amgen-a-buy-2021-04-27 | null | null | Amgen (NASDAQ: AMGN) recently agreed to acquire biotechnology start-up Rodeo Therapeutics in an all-cash deal. Amgen will buy all outstanding shares of Rodeo for a total of $55 million. However, Rodeo stakeholders will be able to receive up to an additional $666 million in cash if certain milestones are met. For invest... | In its 2017 series A funding round, players including AbbVie, Johnson & Johnson, and Eli Lilly invested a combined $5.9 million in it, reflecting their perception of its research's potential. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares of AbbVie. Through this deal, Amgen... | In its 2017 series A funding round, players including AbbVie, Johnson & Johnson, and Eli Lilly invested a combined $5.9 million in it, reflecting their perception of its research's potential. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares of AbbVie. Amgen (NASDAQ: AMGN) rec... | In its 2017 series A funding round, players including AbbVie, Johnson & Johnson, and Eli Lilly invested a combined $5.9 million in it, reflecting their perception of its research's potential. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares of AbbVie. Amgen will buy all outst... | In its 2017 series A funding round, players including AbbVie, Johnson & Johnson, and Eli Lilly invested a combined $5.9 million in it, reflecting their perception of its research's potential. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares of AbbVie. Amgen (NASDAQ: AMGN) rec... |
24,122 | 2021-04-26 00:00:00 UTC | 3 Top Blue-Chip Healthcare Stocks With Healthy Dividends | ABBV | https://www.nasdaq.com/articles/3-top-blue-chip-healthcare-stocks-with-healthy-dividends-2021-04-26 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The healthcare sector is an excellent place to find high-quality companies that produce consistent growth over long periods of time. Because of the continuously strong demand for healthcare, there are many blue-chip healthcare stocks that pay dividends to s... | For context, since 2013, when Abbott spun off AbbVie (NYSE:ABBV), EPS has a compound annual growth rate of 7.8%. The $24 billion purchase of Bard was made primarily from cash, which restricted BD’s ability to grow its dividend over the past few years. BD continues to evolve its business and the company has proven recen... | For context, since 2013, when Abbott spun off AbbVie (NYSE:ABBV), EPS has a compound annual growth rate of 7.8%. Because of the continuously strong demand for healthcare, there are many blue-chip healthcare stocks that pay dividends to shareholders that grow over time. Investors looking for quality blue-chip healthcare... | For context, since 2013, when Abbott spun off AbbVie (NYSE:ABBV), EPS has a compound annual growth rate of 7.8%. These companies are all long-time reliable dividend payers, with two of them just one year away from attaining dividend king status, as their dividend streaks now stand at 49 years. Investors looking for qua... | For context, since 2013, when Abbott spun off AbbVie (NYSE:ABBV), EPS has a compound annual growth rate of 7.8%. Despite low growth over the past few years, the dividend has a compound annual growth rate of almost 9% over the last 10 years. BD’s next increase will mark the company’s 50th consecutive year of dividend gr... |
24,123 | 2021-04-25 00:00:00 UTC | The Best Dividend Stocks to Buy With $300 Right Now | ABBV | https://www.nasdaq.com/articles/the-best-dividend-stocks-to-buy-with-%24300-right-now-2021-04-25 | null | null | You don't have to have a lot of money to start investing. And buying stocks that pay solid dividends gives you additional money on a regular basis to invest even more.
There are two primary things to look for with dividend stocks. The dividend yield -- how much a stock's annual dividend payments are divided by its shar... | Assuming Rinvoq and other drugs in AbbVie's lineup achieve their potential, the company expects to quickly return to growth after Humira loses exclusivity. AbbVie You can currently buy one share of AbbVie (NYSE: ABBV) for around $111. AbbVie's dividend yield stands at 4.7%. | Assuming Rinvoq and other drugs in AbbVie's lineup achieve their potential, the company expects to quickly return to growth after Humira loses exclusivity. AbbVie You can currently buy one share of AbbVie (NYSE: ABBV) for around $111. AbbVie's dividend yield stands at 4.7%. | AbbVie You can currently buy one share of AbbVie (NYSE: ABBV) for around $111. AbbVie's dividend yield stands at 4.7%. The odds look really good that AbbVie's dividends will grow over the long term. | AbbVie You can currently buy one share of AbbVie (NYSE: ABBV) for around $111. AbbVie's dividend yield stands at 4.7%. The odds look really good that AbbVie's dividends will grow over the long term. |
24,124 | 2021-04-24 00:00:00 UTC | This Risk Might Shock Anyone Holding Johnson & Johnson Stock | ABBV | https://www.nasdaq.com/articles/this-risk-might-shock-anyone-holding-johnson-johnson-stock-2021-04-24 | null | null | Before the pandemic, the national health crisis on many people's minds was the opioid epidemic. Between 1999 and 2019, the drugs led to the overdose deaths of more than 500,000 Americans. Although many companies have come under scrutiny for their role in the problem, perhaps none is better-known than Johnson & Johnson ... | Although this one will be conducted virtually, four California counties will begin making the case against Johnson & Johnson, as well as Teva Pharmaceuticals (NYSE: TEVA), Endo International (NASDAQ: ENDP), and Allergan, a division of Abbvie (NYSE: ABBV). Based on Oklahoma's $201 billion gross domestic product (GDP), w... | Although this one will be conducted virtually, four California counties will begin making the case against Johnson & Johnson, as well as Teva Pharmaceuticals (NYSE: TEVA), Endo International (NASDAQ: ENDP), and Allergan, a division of Abbvie (NYSE: ABBV). Based on Oklahoma's $201 billion gross domestic product (GDP), w... | Although this one will be conducted virtually, four California counties will begin making the case against Johnson & Johnson, as well as Teva Pharmaceuticals (NYSE: TEVA), Endo International (NASDAQ: ENDP), and Allergan, a division of Abbvie (NYSE: ABBV). Although many companies have come under scrutiny for their role ... | Although this one will be conducted virtually, four California counties will begin making the case against Johnson & Johnson, as well as Teva Pharmaceuticals (NYSE: TEVA), Endo International (NASDAQ: ENDP), and Allergan, a division of Abbvie (NYSE: ABBV). In 2019, the company was ordered to pay $465 million for its rol... |
24,125 | 2021-04-24 00:00:00 UTC | 3 Bargain Stocks to Buy With the Market Near All-Time Highs | ABBV | https://www.nasdaq.com/articles/3-bargain-stocks-to-buy-with-the-market-near-all-time-highs-2021-04-24 | null | null | Let's face it: Most stocks are expensive right now. The cyclically adjusted price-to-earnings ratio (or CAPE ratio) popularized by economist Robert Shiller is at its highest level since 2000. There aren't many stocks trading at a discount these days.
But there are still a few stocks with attractive valuations and solid... | AbbVie AbbVie (NYSE: ABBV) currently trades at only 8.7 times expected earnings. By comparison, the forward earnings multiple for the S&P 500 index (of which AbbVie is a member) is over 22. Why is AbbVie so cheap? | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. AbbVie AbbVie (NYSE: ABBV) currently trades at only 8.7 times expected earnings. By comparison, the forward earnings multiple for the S&P 500 index (of which Ab... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. AbbVie AbbVie (NYSE: ABBV) currently trades at only 8.7 times expected earnings. By comparison, the forward earnings multiple for the S&P 500 index (of which Ab... | Bristol Myers Squibb AbbVie isn't the only attractively valued big pharma. AbbVie was one of the other two stocks. AbbVie AbbVie (NYSE: ABBV) currently trades at only 8.7 times expected earnings. |
24,126 | 2021-04-23 00:00:00 UTC | AbbVie Announces Positive CHMP Opinion For VENCLYXTO In Acute Myeloid Leukemia | ABBV | https://www.nasdaq.com/articles/abbvie-announces-positive-chmp-opinion-for-venclyxto-in-acute-myeloid-leukemia-2021-04-23 | null | null | (RTTNews) - AbbVie (ABBV) said the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for VENCLYXTO in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemothe... | (RTTNews) - AbbVie (ABBV) said the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for VENCLYXTO in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemothe... | (RTTNews) - AbbVie (ABBV) said the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for VENCLYXTO in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemothe... | (RTTNews) - AbbVie (ABBV) said the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for VENCLYXTO in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemothe... | (RTTNews) - AbbVie (ABBV) said the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for VENCLYXTO in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemothe... |
24,127 | 2021-04-22 00:00:00 UTC | AbbVie's Humira Gets Approval In Canada For Treatment Of Pediatric Patients With Ulcerative Colitis | ABBV | https://www.nasdaq.com/articles/abbvies-humira-gets-approval-in-canada-for-treatment-of-pediatric-patients-with-ulcerative | null | null | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) Thursday said Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis.
With this approval, Humira offers pediatric patients w... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) Thursday said Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis. With this approval, Humira offers pediatric patients w... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) Thursday said Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis. With this approval, Humira offers pediatric patients w... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) Thursday said Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis. Although we are able to treat a lot of children who ha... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) Thursday said Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis. With this approval, Humira offers pediatric patients w... |
24,128 | 2021-04-21 00:00:00 UTC | 3 Stocks for a Better Retirement | ABBV | https://www.nasdaq.com/articles/3-stocks-for-a-better-retirement-2021-04-21 | null | null | When it comes to investing for your retirement or investing in retirement, it's hard to beat dividend-paying stocks. No matter what the overall economy is doing, as long as a dividend-paying company is healthy, it will keep sending you regular infusions of cash. That money can be used for expenses in retirement or to b... | But those worrying about that may be forgetting that AbbVie has plenty of formulas in its pipeline, some of which are likely to eventually win approval from the U.S. Food and Drug Administration (FDA). AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV), with a recent market value near $191 billion, is another promising co... | With its price-to-sales ratio, price-to-cash-flow ratio, and forward-looking price-to-earnings (P/E) ratio all recently below their five-year averages, AbbVie stock looks undervalued -- while offering a tantalizing dividend yield, too. AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV), with a recent market value near $19... | With its price-to-sales ratio, price-to-cash-flow ratio, and forward-looking price-to-earnings (P/E) ratio all recently below their five-year averages, AbbVie stock looks undervalued -- while offering a tantalizing dividend yield, too. AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV), with a recent market value near $19... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Selena Maranjian owns shares of AbbVie and W. P. Carey. AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV), with a recent market value near $191 billion, is another promising company that can help you build a better retirement. But those worrying about that ... |
24,129 | 2021-04-19 00:00:00 UTC | J&J, other drugmakers go to trial in California in $50 bln case over 'deadly legacy' of opioids | ABBV | https://www.nasdaq.com/articles/jj-other-drugmakers-go-to-trial-in-california-in-%2450-bln-case-over-deadly-legacy-of | null | null | By Nate Raymond and Brendan Pierson
April 19 (Reuters) - Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the start of multibillion-dollar trial.
Those counties accuse Joh... | Those counties accuse Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International Plc ENDP.O and AbbVie's ABBV.N Allergan unit of fueling a drug crisis that according to the U.S. government resulted in nearly 500,000 opioid overdose deaths over two decades. By Nate Raymond and Brendan Pierso... | Those counties accuse Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International Plc ENDP.O and AbbVie's ABBV.N Allergan unit of fueling a drug crisis that according to the U.S. government resulted in nearly 500,000 opioid overdose deaths over two decades. By Nate Raymond and Brendan Pierso... | Those counties accuse Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International Plc ENDP.O and AbbVie's ABBV.N Allergan unit of fueling a drug crisis that according to the U.S. government resulted in nearly 500,000 opioid overdose deaths over two decades. By Nate Raymond and Brendan Pierso... | Those counties accuse Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International Plc ENDP.O and AbbVie's ABBV.N Allergan unit of fueling a drug crisis that according to the U.S. government resulted in nearly 500,000 opioid overdose deaths over two decades. By Nate Raymond and Brendan Pierso... |
24,130 | 2021-04-19 00:00:00 UTC | J&J, others face California trial over claims they fueled opioid epidemic | ABBV | https://www.nasdaq.com/articles/jj-others-face-california-trial-over-claims-they-fueled-opioid-epidemic-2021-04-19 | null | null | By Nate Raymond
April 19 (Reuters) - Four drugmakers are set to face trial on Monday in a lawsuit by several large counties in California that are seeking more than $50 billion over claims the companies helped fuel an opioid epidemic by deceptively marketing addictive painkillers.
The case against Johnson & Johnson JNJ... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... |
24,131 | 2021-04-19 00:00:00 UTC | J&J, other drugmakers to face trial in California over claims they fueled opioid epidemic | ABBV | https://www.nasdaq.com/articles/jj-other-drugmakers-to-face-trial-in-california-over-claims-they-fueled-opioid-epidemic | null | null | By Nate Raymond
April 19 (Reuters) - Four drugmakers are set to face trial on Monday in a lawsuit by several large counties in California that are seeking more than $50 billion over claims the companies helped fuel an opioid epidemic by deceptively marketing addictive painkillers.
The case against Johnson & Johnson JNJ... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... | The case against Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie's ABBV.N Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. By Nate Raymond April 19 (Re... |
24,132 | 2021-04-16 00:00:00 UTC | Drug companies to face first opioid trial following pandemic delays | ABBV | https://www.nasdaq.com/articles/drug-companies-to-face-first-opioid-trial-following-pandemic-delays-2021-04-16 | null | null | By Nate Raymond and Brendan Pierson
April 16 (Reuters) - Four drugmakers, including Johnson & Johnson and Teva Pharmaceutical Industries Ltd , will go to trial on Monday over claims they helped fuel an opioid crisis that has resulted in nearly 500,000 overdose deaths in the United States.
The trial is one of several lo... | J&J, Teva Pharmaceutical Industries Ltd , Endo International PLC and Abbvie's Allergan unit are accused by several California counties of deceptively marketing painkillers in ways that downplayed their addictive risks to boost sales. The trial is one of several looking to hold companies accountable for the overdose and... | J&J, Teva Pharmaceutical Industries Ltd , Endo International PLC and Abbvie's Allergan unit are accused by several California counties of deceptively marketing painkillers in ways that downplayed their addictive risks to boost sales. By Nate Raymond and Brendan Pierson April 16 (Reuters) - Four drugmakers, including Jo... | J&J, Teva Pharmaceutical Industries Ltd , Endo International PLC and Abbvie's Allergan unit are accused by several California counties of deceptively marketing painkillers in ways that downplayed their addictive risks to boost sales. By Nate Raymond and Brendan Pierson April 16 (Reuters) - Four drugmakers, including Jo... | J&J, Teva Pharmaceutical Industries Ltd , Endo International PLC and Abbvie's Allergan unit are accused by several California counties of deceptively marketing painkillers in ways that downplayed their addictive risks to boost sales. By Nate Raymond and Brendan Pierson April 16 (Reuters) - Four drugmakers, including Jo... |
24,133 | 2021-04-15 00:00:00 UTC | 2 Best Reddit Healthcare Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/2-best-reddit-healthcare-stocks-to-buy-now-2021-04-15 | null | null | Over the past quarter, traders of the legendary r/WallStreetBets have propelled shares of GameStop, AMC Entertainment Holdings, and BlackBerry to some mouth-watering (albeit roller-coaster-like) returns. The same group of investors is now eyeing two medical stocks, Trevena (NASDAQ: TRVN) and Tonix Pharmaceuticals (NASD... | The last medication approved to treat fibromyalgia, AbbVie's (NYSE: ABBV) Savella, still managed to hit $130 million in peak sales despite only marginally improving patients' condition. As investors know, a company's valuation isn't only about how much cash flow it generates, but also about future earnings potential ba... | The last medication approved to treat fibromyalgia, AbbVie's (NYSE: ABBV) Savella, still managed to hit $130 million in peak sales despite only marginally improving patients' condition. The same group of investors is now eyeing two medical stocks, Trevena (NASDAQ: TRVN) and Tonix Pharmaceuticals (NASDAQ: TNXP). Trevena... | The last medication approved to treat fibromyalgia, AbbVie's (NYSE: ABBV) Savella, still managed to hit $130 million in peak sales despite only marginally improving patients' condition. The same group of investors is now eyeing two medical stocks, Trevena (NASDAQ: TRVN) and Tonix Pharmaceuticals (NASDAQ: TNXP). Trevena... | The last medication approved to treat fibromyalgia, AbbVie's (NYSE: ABBV) Savella, still managed to hit $130 million in peak sales despite only marginally improving patients' condition. Trevena and Tonix stocks are up almost 250% and 55%, respectively, over the past 12 months. Trevena Right now, Trevena has no product ... |
24,134 | 2021-04-15 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2021-04-15 | null | null | Recently, a young woman told me that her husband wanted to invest in dividend stocks. Both of them are in their twenties. My response to her was that at their age, they'd be better off focusing on stocks with solid long-term growth prospects, regardless of whether or not the stocks paid dividends.
My reply would have b... | A single product, Humira, generated over 40% of AbbVie's total revenue last year, but the autoimmune-disease drug loses U.S. patent exclusivity in 2023. AbbVie I think that AbbVie (NYSE: ABBV) ranks as one of the most attractive dividend stocks on the market right now. AbbVie is only one dividend hike away from becomin... | Brookfield Renewable Partners Brookfield Renewable Partners (NYSE: BEP) doesn't belong to dividend royalty as AbbVie does. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Enterprise Products Partners. AbbVie I think that AbbV... | Brookfield Renewable Partners Brookfield Renewable Partners (NYSE: BEP) doesn't belong to dividend royalty as AbbVie does. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Enterprise Products Partners. AbbVie I think that AbbV... | AbbVie I think that AbbVie (NYSE: ABBV) ranks as one of the most attractive dividend stocks on the market right now. AbbVie is only one dividend hike away from becoming a Dividend King -- S&P 500 members with at least 50 consecutive years of dividend increases. A single product, Humira, generated over 40% of AbbVie's t... |
24,135 | 2021-04-14 00:00:00 UTC | Got $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/got-%241000-2-dirt-cheap-value-stocks-you-can-buy-right-now-2021-04-14 | null | null | There are good reasons to think that stocks in general are currently dangerously overvalued. For instance, the S&P 500's cyclically adjusted price-to-earnings ratio -- a measure of the stock market's valuation -- is currently 36.6, the highest it has been in more than 10 years.
Fortunately, even in a market where rich ... | But there is a lot more to like about AbbVie than its low valuation metrics, even though the company's crown jewel -- the rheumatoid arthritis drug Humira -- continues to lose steam in Europe due to competition from biosimilars. Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie AbbVie... | AbbVie AbbVie currently trades for just 8.7 times forward earnings, while its price-to-earnings growth ratio (PEG) is 0.19. Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). But there is a lot more to like about AbbVie than its low valuation metrics, even though the company's crown jewel -- ... | These factors all bode well for AbbVie, and even though the stock has underperformed the market in the past 12 months, investors willing to be patient would do well to consider buying shares of this pharma stock. Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie AbbVie currently trade... | Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie AbbVie currently trades for just 8.7 times forward earnings, while its price-to-earnings growth ratio (PEG) is 0.19. But there is a lot more to like about AbbVie than its low valuation metrics, even though the company's crown jewel -- ... |
24,136 | 2021-04-14 00:00:00 UTC | Should AbbVie Be Worried About Rinvoq? | ABBV | https://www.nasdaq.com/articles/should-abbvie-be-worried-about-rinvoq-2021-04-14 | null | null | The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. This autoimmune disease drug is an important component of the company's growth strategy. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speight... | AbbVie announced on April 2 that the FDA has pushed back the review period for Rinvoq in treating atopic dermatitis by three months. Now, AbbVie's counting on Rinvoq to be a key part of its strategy to offset the expected decline in sales for Humira when that top-selling drug loses patent exclusivity in 2023. The U.S. ... | In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq. AbbVie announced on April 2 that the FDA has pushed back the review period for Rinvoq in treating atopic dermatitis by th... | The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried a... | In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights: AbbVie -- ticker there's ABBV. The U.S. ... |
24,137 | 2021-04-14 00:00:00 UTC | Is Morphic Holding a Buy? | ABBV | https://www.nasdaq.com/articles/is-morphic-holding-a-buy-2021-04-14 | null | null | On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its experimental therapy, MORF-057. That's a pretty significant pop for an under-the-radar biotech, especially based on data that comes from so early in a drug's clinical trial process.
Since then, t... | Even though the company is still in the early stages of drug development, it has attracted big-name partners like Johnson & Johnson's (NYSE: JNJ) Janssen subsidiary and AbbVie (NYSE: ABBV). On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its exper... | Even though the company is still in the early stages of drug development, it has attracted big-name partners like Johnson & Johnson's (NYSE: JNJ) Janssen subsidiary and AbbVie (NYSE: ABBV). On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its exper... | Even though the company is still in the early stages of drug development, it has attracted big-name partners like Johnson & Johnson's (NYSE: JNJ) Janssen subsidiary and AbbVie (NYSE: ABBV). On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its exper... | Even though the company is still in the early stages of drug development, it has attracted big-name partners like Johnson & Johnson's (NYSE: JNJ) Janssen subsidiary and AbbVie (NYSE: ABBV). On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its exper... |
24,138 | 2021-04-13 00:00:00 UTC | Noteworthy Tuesday Option Activity: WDC, FDX, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-wdc-fdx-abbv-2021-04-13 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Western Digital Corp (Symbol: WDC), where a total of 31,523 contracts have traded so far, representing approximately 3.2 million underlying shares. That amounts to about 74.1% of WDC's average daily trading volume ov... | Especially high volume was seen for the $105 strike call option expiring April 16, 2021, with 7,267 contracts trading so far today, representing approximately 726,700 underlying shares of ABBV. Below is a chart showing FDX's trailing twelve month trading history, with the $300 strike highlighted in orange: And AbbVie I... | Below is a chart showing FDX's trailing twelve month trading history, with the $300 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 48,093 contracts thus far today. That number of contracts represents approximately 4.8 million underlying shares, working out to a sizeable 61.3... | Especially high volume was seen for the $105 strike call option expiring April 16, 2021, with 7,267 contracts trading so far today, representing approximately 726,700 underlying shares of ABBV. Below is a chart showing FDX's trailing twelve month trading history, with the $300 strike highlighted in orange: And AbbVie I... | Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: For the various different available expirations for WDC options, FDX options, or ABBV options, visit StockOptionsChannel.com. Below is a chart showing FDX's trailing twelve month trading history, with the ... |
24,139 | 2021-04-13 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for April 14, 2021 | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-ex-dividend-date-scheduled-for-april-14-2021-2021-04-13 | null | null | AbbVie Inc. (ABBV) will begin trading ex-dividend on April 14, 2021. A cash dividend payment of $1.3 per share is scheduled to be paid on May 14, 2021. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 10.17% increase over prior dividend payment... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2021 as 18.37%, compared to an industry average of 8.4%. For more information on the declaration, record and payment dates, visit the ABBV Divi... | ABBV's current earnings per share, an indicator of a company's profitability, is $2.86. The following ETF(s) have ABBV as a top-10 holding: First Trust Morningstar ETF (FDL) First Trust Nasdaq Pharmaceuticals ETF (FTXH) iShares U.S. ETF Trust (IEIH) Invesco Dynamic Pharmaceuticals ETF (PJP) VanEck Vectors Pharmaceutica... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: First Trust Morningstar ETF (FDL) First Trust Nasdaq Phar... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. ABBV's current earnings per share, an indicator of a company's profitability, is $2.86. AbbVie Inc. (ABBV) will begin trading ex-dividend on April 14, 2021. |
24,140 | 2021-04-13 00:00:00 UTC | A Short Delay Is Still Bad News for AbbVie | ABBV | https://www.nasdaq.com/articles/a-short-delay-is-still-bad-news-for-abbvie-2021-04-13 | null | null | The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. On the surface, a three-month delay isn't a huge deal for the large drugmaker. But as Fool.com Contributors Brian Orelli and Keith Speights discuss in this video from Motley Fool Live, recorded on March 22, the extensio... | The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy rig... | The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Brian Orelli: So, last week, AbbVie said that the FDA is extending its review of Rinvoq as a treatment for psoriatic arthritis. So if any company can get an approval for a JAK inhibitor for these indications, I think it would be AbbVie. The FDA extended t... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Brian Orelli: So, last week, AbbVie said that the FDA is extending its review of Rinvoq as a treatment for psoriatic arthritis. So if any company can get an approval for a JAK inhibitor for these indications, I think it would be AbbVie. The FDA extended t... |
24,141 | 2021-04-13 00:00:00 UTC | 2 Stocks That Are Perfect to Buy Now and Hold Until Retirement | ABBV | https://www.nasdaq.com/articles/2-stocks-that-are-perfect-to-buy-now-and-hold-until-retirement-2021-04-13 | null | null | Investors approaching retirement tend to be focused on investing prudently in those last few years before leaving the workforce, with many seeking to maximize their dividend income. Two companies in the healthcare sector stand out as good prospects in that regard, both now and in the future: AbbVie (NYSE: ABBV) and Pfi... | AbbVie has several leading products, including Humira (for Crohn's disease), Skyrizi (for psoriasis), and Rinvoq (for rheumatoid arthritis), all of which have helped drive returns of nearly 222% since inception. Such blockbuster drugs have contributed to remarkable revenue growth since inception, with earnings per shar... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares of Bristol Myers Squibb, Pfizer, AbbVie, and Merck. Two companies in the healthcare sector stand out as good prospects in that regard, both now and in the future: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie: Buy while it... | Investing in healthcare companies like AbbVie and Pfizer -- businesses that offer both share-price appreciation and a 4%-plus dividend yield -- can help you secure a profitable retirement. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares of Bristol Myers Squibb, Pfizer, AbbVi... | Two companies in the healthcare sector stand out as good prospects in that regard, both now and in the future: AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie: Buy while it's still cheap AbbVie came on to the market in 2013 after being spun off from medical device company Abbott Labs. AbbVie has several leading prod... |
24,142 | 2021-04-12 00:00:00 UTC | COVID SCIENCE-Autoimmune-disease drugs may reduce vaccine response; antibody treatments ineffective vs Brazil variant | ABBV | https://www.nasdaq.com/articles/covid-science-autoimmune-disease-drugs-may-reduce-vaccine-response-antibody-treatments | null | null | By Nancy Lapid
April 12 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Autoimmune disease treatments may reduce vaccine responses
Immunosuppressive drugs for inflammatory ... | Reductions in antibody levels were more modest with widely used rheumatoid arthritis drugs in the class known as TNF inhibitors such as Abbvie's ABBV.N Humira (adalimumab) and Amgen's AMGN.O Enbrel (etanercept); antimetabolites like methotrexate and sulfasalazine; JAK inhibitors like Pfizer's Xeljanz (tofacitinib), gut... | Reductions in antibody levels were more modest with widely used rheumatoid arthritis drugs in the class known as TNF inhibitors such as Abbvie's ABBV.N Humira (adalimumab) and Amgen's AMGN.O Enbrel (etanercept); antimetabolites like methotrexate and sulfasalazine; JAK inhibitors like Pfizer's Xeljanz (tofacitinib), gut... | Reductions in antibody levels were more modest with widely used rheumatoid arthritis drugs in the class known as TNF inhibitors such as Abbvie's ABBV.N Humira (adalimumab) and Amgen's AMGN.O Enbrel (etanercept); antimetabolites like methotrexate and sulfasalazine; JAK inhibitors like Pfizer's Xeljanz (tofacitinib), gut... | Reductions in antibody levels were more modest with widely used rheumatoid arthritis drugs in the class known as TNF inhibitors such as Abbvie's ABBV.N Humira (adalimumab) and Amgen's AMGN.O Enbrel (etanercept); antimetabolites like methotrexate and sulfasalazine; JAK inhibitors like Pfizer's Xeljanz (tofacitinib), gut... |
24,143 | 2021-04-11 00:00:00 UTC | 4 Green Flags for AbbVie in 2021 | ABBV | https://www.nasdaq.com/articles/4-green-flags-for-abbvie-in-2021-2021-04-11 | null | null | Given that AbbVie (NYSE: ABBV) is one of the largest pharma companies in the world, one might expect that it has a limited number of opportunities to deliver substantial growth to its investors. But the pharma giant is anything but complacent, and its work is always paying off in the form of new revenue streams that en... | 12 upcoming new data readouts from late-stage clinical trials While getting new information about its ongoing projects might not move AbbVie's stock price as much as it could for a smaller company, investors can still look forward to positive news supporting higher valuations. Even as Humira will face mounting competit... | While it's true that the company will face headwinds once its best-selling drug Humira starts facing serious competition from generics in the U.S., AbbVie is intent on making the transition as smooth as possible for investors. Humira secures yet another approval In late February, AbbVie announced that its best-selling ... | 12 upcoming new data readouts from late-stage clinical trials While getting new information about its ongoing projects might not move AbbVie's stock price as much as it could for a smaller company, investors can still look forward to positive news supporting higher valuations. Humira secures yet another approval In lat... | 12 upcoming new data readouts from late-stage clinical trials While getting new information about its ongoing projects might not move AbbVie's stock price as much as it could for a smaller company, investors can still look forward to positive news supporting higher valuations. Given that AbbVie (NYSE: ABBV) is one of t... |
24,144 | 2021-04-11 00:00:00 UTC | 3 Great Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-to-buy-right-now-2021-04-11 | null | null | You really only have to look for two things when considering dividend stocks. First, the stock has to pay a dividend. Second, the business behind the stock should be strong enough to keep the dividends coming.
Sure, there are other characteristics of dividend stocks that are nice to have. A relatively high yield would ... | That's going to make a serious dent in AbbVie's revenue, considering that Humira generated 43% of the company's total sales last year. AbbVie does expect total sales to slip in 2023 with Humira losing market share to biosimilar rivals in the U.S. AbbVie AbbVie (NYSE: ABBV) has paid a dividend since 1924, including the ... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., Pfizer, and Viatris. AbbVie AbbVie (NYSE: ABBV) has paid a dividend since 1924, including the time when the company was still part of Abbott Labs. The drugmaker has increased its di... | The drugmaker has increased its dividend for 49 consecutive years, qualifying AbbVie as a Dividend Aristocrat that's knocking on the door of becoming a Dividend King. AbbVie AbbVie (NYSE: ABBV) has paid a dividend since 1924, including the time when the company was still part of Abbott Labs. There's one glaring issue w... | That's going to make a serious dent in AbbVie's revenue, considering that Humira generated 43% of the company's total sales last year. AbbVie AbbVie (NYSE: ABBV) has paid a dividend since 1924, including the time when the company was still part of Abbott Labs. The drugmaker has increased its dividend for 49 consecutive... |
24,145 | 2021-04-10 00:00:00 UTC | Better Value Stock: AbbVie or Viatris? | ABBV | https://www.nasdaq.com/articles/better-value-stock%3A-abbvie-or-viatris-2021-04-10 | null | null | Most stocks are expensive right now. That's to be expected with major market indexes at or near all-time highs. Amid the premium prices, though, there are still a few bargains to be found.
Two drugmakers -- AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) -- especially stand out due to their attractive valuations. Which ... | While investors are worried about the impact of declining sales for Humira with AbbVie, Viatris's product lineup is chock-full of drugs that are past their prime. Some might be anxious that the U.S. Food and Drug Administration (FDA) has pushed back the review period for Rinvoq for AbbVie's regulatory filings for atopi... | While investors are worried about the impact of declining sales for Humira with AbbVie, Viatris's product lineup is chock-full of drugs that are past their prime. AbbVie should deliver strong sales growth in 2021 and 2022. Two drugmakers -- AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) -- especially stand out due to t... | The two stocks are pretty close on this metric, with AbbVie's EV/EBITDA of 21.5 just a little higher than Viatris's multiple of nearly 21. My view is that while Viatris has a lower valuation based on nearly any metric you use, AbbVie is the better value stock. See the 10 stocks *Stock Advisor returns as of February 24,... | AbbVie's P/E multiple currently stands at 39, while Viatris's P/E ratio is over 28.5. Two drugmakers -- AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) -- especially stand out due to their attractive valuations. Here's how AbbVie and Viatris stack up against each other. |
24,146 | 2021-04-09 00:00:00 UTC | Interesting ABBV Put And Call Options For June 18th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-june-18th-2021-04-09 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the June 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 70 days until expiration the newly trading contracts represent a potential opportunity for sellers o... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing ABBV's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 18th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $115.00 strike highlighted in red: Consideri... |
24,147 | 2021-04-09 00:00:00 UTC | Do These 3 Checks Before Buying AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend | ABBV | https://www.nasdaq.com/articles/do-these-3-checks-before-buying-abbvie-inc.-nyse%3Aabbv-for-its-upcoming-dividend-2021-04-09 | null | null | Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see AbbVie Inc. (NYSE:ABBV) is about to trade ex-dividend in the next four days. This means that investors who purchase shares on or after the 14th of April will not receive the dividend, which will be paid on the 14th... | Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see AbbVie Inc. (NYSE:ABBV) is about to trade ex-dividend in the next four days. Yet cashflow was much stronger, which makes us wonder if there are some large timing issues in AbbVie's cash flows, or perhaps the compan... | A useful secondary check can be to evaluate whether AbbVie generated enough free cash flow to afford its dividend. It's disappointing to see that the dividend was not covered by profits, but cash is more important from a dividend sustainability perspective, and AbbVie fortunately did generate enough cash to fund its di... | It's disappointing to see that the dividend was not covered by profits, but cash is more important from a dividend sustainability perspective, and AbbVie fortunately did generate enough cash to fund its dividend. AbbVie has delivered an average of 16% per year annual increase in its dividend, based on the past eight ye... | AbbVie paid out 177% of profit in the past year, which we think is typically not sustainable unless there are mitigating characteristics such as unusually strong cash flow or a large cash balance. Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see AbbVie Inc. (NYSE... |
24,148 | 2021-04-08 00:00:00 UTC | Interesting ABBV Put And Call Options For May 28th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-may-28th-2021-04-08 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 28th contracts and identified one put and one call contract of particular interest.
The put contract ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $105.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $1.29. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 28th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considerin... |
24,149 | 2021-04-08 00:00:00 UTC | IVW, ABBV, INTU, NOW: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/ivw-abbv-intu-now%3A-etf-outflow-alert-2021-04-08 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $70.9 million dollar outflow -- that's a 0.2% decrease week over week (from 479,450,000 to 478,400,000). Among ... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 1%, Intuit Inc (Symbol: INTU) is up about 1.7%, and ServiceNow Inc (Symbol: NOW) is higher by about 2.4%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 1%, Intuit Inc (Symbol: INTU) is up about 1.7%, and ServiceNow Inc (Symbol: NOW) is higher by about 2.4%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 1%, Intuit Inc (Symbol: INTU) is up about 1.7%, and ServiceNow Inc (Symbol: NOW) is higher by about 2.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, o... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 1%, Intuit Inc (Symbol: INTU) is up about 1.7%, and ServiceNow Inc (Symbol: NOW) is higher by about 2.4%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perform... |
24,150 | 2021-04-07 00:00:00 UTC | Does 2021's Best Biopharma to Work for Belong in Your Portfolio? | ABBV | https://www.nasdaq.com/articles/does-2021s-best-biopharma-to-work-for-belong-in-your-portfolio-2021-04-07 | null | null | Happy employees can create effective companies. So when a business makes it onto Fortune magazine's "Best Workplaces" list five years in a row, it suggests that employees are content, and shareholders are likely being handsomely rewarded in the process.
Consider Horizon Therapeutics (NASDAQ: HZNP), which topped the mag... | The best-selling drug of 2019, AbbVie's (NYSE: ABBV) Humira, sold $852 million in its first full year on the market (2004), and the second-best-selling drug of 2019, Bristol Myers Squibb's (NYSE: BMY) and Pfizer's (NYSE: PFE) Eliquis, sold $770 million in its first full year on the market (2014). So when a business mak... | The best-selling drug of 2019, AbbVie's (NYSE: ABBV) Humira, sold $852 million in its first full year on the market (2004), and the second-best-selling drug of 2019, Bristol Myers Squibb's (NYSE: BMY) and Pfizer's (NYSE: PFE) Eliquis, sold $770 million in its first full year on the market (2014). The Motley Fool owns s... | The best-selling drug of 2019, AbbVie's (NYSE: ABBV) Humira, sold $852 million in its first full year on the market (2004), and the second-best-selling drug of 2019, Bristol Myers Squibb's (NYSE: BMY) and Pfizer's (NYSE: PFE) Eliquis, sold $770 million in its first full year on the market (2014). The company already ex... | The best-selling drug of 2019, AbbVie's (NYSE: ABBV) Humira, sold $852 million in its first full year on the market (2004), and the second-best-selling drug of 2019, Bristol Myers Squibb's (NYSE: BMY) and Pfizer's (NYSE: PFE) Eliquis, sold $770 million in its first full year on the market (2014). Consider Horizon Thera... |
24,151 | 2021-04-06 00:00:00 UTC | Should You Buy AbbVie in April? | ABBV | https://www.nasdaq.com/articles/should-you-buy-abbvie-in-april-2021-04-06 | null | null | AbbVie (NYSE: ABBV) is one of those stocks that should be in everyone's portfolio. It's rare to find its mix of growth and value (plus a really good dividend). The pharmaceutical company has enjoyed a run of six consecutive years of double-digit earnings per share (EPS) growth, and management says they expect more of t... | Last year, the company purchased Allergan, which -- because of its roughly $16 billion in annual revenue prior to the sale -- boosts AbbVie's cash flow for research and development. AbbVie is also awaiting a decision on its New Drug Application (NDA) for AGN-190584 to combat age-related eye disease presbyopia. The comp... | AbbVie (NYSE: ABBV) is one of those stocks that should be in everyone's portfolio. AbbVie expects adjusted diluted EPS for full-year 2021 of $12.32 to $12.52. Image source: Getty Images It's important to look past Humira A lot of investors are concerned about what biosimilar competition in the U.S. will do to the sales... | AbbVie (NYSE: ABBV) is one of those stocks that should be in everyone's portfolio. AbbVie expects adjusted diluted EPS for full-year 2021 of $12.32 to $12.52. Image source: Getty Images It's important to look past Humira A lot of investors are concerned about what biosimilar competition in the U.S. will do to the sales... | AbbVie (NYSE: ABBV) is one of those stocks that should be in everyone's portfolio. AbbVie expects adjusted diluted EPS for full-year 2021 of $12.32 to $12.52. Image source: Getty Images It's important to look past Humira A lot of investors are concerned about what biosimilar competition in the U.S. will do to the sales... |
24,152 | 2021-04-06 00:00:00 UTC | What Kind Of Shareholders Hold The Majority In AbbVie Inc.'s (NYSE:ABBV) Shares? | ABBV | https://www.nasdaq.com/articles/what-kind-of-shareholders-hold-the-majority-in-abbvie-inc.s-nyse%3Aabbv-shares-2021-04-06 | null | null | If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. We also tend to see lower insider ownership in companie... | NYSE:ABBV Earnings and Revenue Growth April 6th 2021 Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look at the makeup of its share registry. AbbVie ... | NYSE:ABBV Earnings and Revenue Growth April 6th 2021 Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look at the makeup of its share registry. AbbVie ... | We can see that AbbVie does have institutional investors; and they hold a good portion of the company's stock. Insider Ownership Of AbbVie The definition of company insiders can be subjective and does vary between jurisdictions. If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look a... | We can see that AbbVie does have institutional investors; and they hold a good portion of the company's stock. NYSE:ABBV Earnings and Revenue Growth April 6th 2021 Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. If you want to know who... |
24,153 | 2021-04-04 00:00:00 UTC | 3 Dividend Stocks That Are Perfect for Retirement | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-are-perfect-for-retirement-2021-04-04 | null | null | Most retirees will want to stay far away from "meme stocks." Such stocks skyrocket due to online hype rather than their underlying business performance. Their gains could easily evaporate, leaving your retirement account in shambles.
Retired investors are much better off going with the stocks of strong companies that p... | AbbVie To qualify as a Dividend King, a member of the S&P 500 must increase its dividend for 50 consecutive years. AbbVie (NYSE: ABBV) is only one dividend hike away from moving into this highest echelon of dividend royalty. The big drugmaker has raised its dividend for 49 consecutive years, which qualifies AbbVie as a... | Brookfield Renewable Partners Brookfield Renewable Partners' (NYSE: BEP) current dividend yield of 4.6% isn't too far behind AbbVie's. Johnson & Johnson While AbbVie isn't a Dividend King just yet, Johnson & Johnson (NYSE: JNJ) has been a member of the elite group for nearly a decade. AbbVie To qualify as a Dividend Ki... | But AbbVie offers more than just a great dividend program: The company is set to deliver solid long-term growth as well. Brookfield Renewable Partners Brookfield Renewable Partners' (NYSE: BEP) current dividend yield of 4.6% isn't too far behind AbbVie's. Johnson & Johnson While AbbVie isn't a Dividend King just yet, J... | AbbVie To qualify as a Dividend King, a member of the S&P 500 must increase its dividend for 50 consecutive years. AbbVie (NYSE: ABBV) is only one dividend hike away from moving into this highest echelon of dividend royalty. The big drugmaker has raised its dividend for 49 consecutive years, which qualifies AbbVie as a... |
24,154 | 2021-04-03 00:00:00 UTC | 11 Words From President Biden That Frighten Big Pharma | ABBV | https://www.nasdaq.com/articles/11-words-from-president-biden-that-frighten-big-pharma-2021-04-03 | null | null | Just about everybody working in America agrees that the country's crumbling infrastructure needs more investment. Behind closed doors, though, America's largest pharmaceutical companies probably want the American Jobs Plan to just go away. That's because big pharmaceutical companies have been heavily incentivized to mo... | Here's why provisions buried in the fine print of the American Jobs Plan could mean trouble for companies that generate most of their profits in the U.S. like Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). AbbVie's operations are generating nearly three times as much cash as they were in 2017, but the company's... | AbbVie reported an effective income tax rate of negative 36% last year and the company's provision for income taxes made a deep dive into negative territory, thanks to a parade of tax loopholes related to foreign income. Here's why provisions buried in the fine print of the American Jobs Plan could mean trouble for com... | AbbVie reported an effective income tax rate of negative 36% last year and the company's provision for income taxes made a deep dive into negative territory, thanks to a parade of tax loopholes related to foreign income. Here's why provisions buried in the fine print of the American Jobs Plan could mean trouble for com... | AbbVie's operations are generating nearly three times as much cash as they were in 2017, but the company's tax bills have gotten a lot smaller. Here's why provisions buried in the fine print of the American Jobs Plan could mean trouble for companies that generate most of their profits in the U.S. like Johnson & Johnson... |
24,155 | 2021-04-02 00:00:00 UTC | AbbVie : FDA Extends Review Period For SNDA Of Upadacitinib For Treatment Of Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-fda-extends-review-period-for-snda-of-upadacitinib-for-treatment-of-atopic | null | null | (RTTNews) - AbbVie (ABBV) said Friday that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
The Prescription Drug User Fee Act or PDUFA action date ... | (RTTNews) - AbbVie (ABBV) said Friday that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis. AbbVie received an information request from the FDA for ... | (RTTNews) - AbbVie (ABBV) said Friday that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis. AbbVie received an information request from the FDA for ... | (RTTNews) - AbbVie (ABBV) said Friday that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis. AbbVie responded to the request and the FDA has informed... | (RTTNews) - AbbVie (ABBV) said Friday that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis. AbbVie received an information request from the FDA for ... |
24,156 | 2021-04-01 00:00:00 UTC | AbbVie : Upadacitinib Improves Clinical And Radiographic Outcomes In Psoriatic Arthritis People | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-upadacitinib-improves-clinical-and-radiographic-outcomes-in-psoriatic-arthritis | null | null | (RTTNews) - AbbVie (ABBV) said that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modi... | (RTTNews) - AbbVie (ABBV) said that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modi... | (RTTNews) - AbbVie (ABBV) said that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modi... | (RTTNews) - AbbVie (ABBV) said that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modi... | (RTTNews) - AbbVie (ABBV) said that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modi... |
24,157 | 2021-03-31 00:00:00 UTC | Noteworthy ETF Inflows: IWF, GOOG, UNH, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-iwf-goog-unh-abbv-2021-03-31 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.0 million dollar inflow -- that's a 0.1% increase week over week in outstanding units (from 260,000,00... | Among the largest underlying components of IWF, in trading today Alphabet Inc (Symbol: GOOG) is up about 1.1%, UnitedHealth Group Inc (Symbol: UNH) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.5%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year pri... | Among the largest underlying components of IWF, in trading today Alphabet Inc (Symbol: GOOG) is up about 1.1%, UnitedHealth Group Inc (Symbol: UNH) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.5%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year pri... | Among the largest underlying components of IWF, in trading today Alphabet Inc (Symbol: GOOG) is up about 1.1%, UnitedHealth Group Inc (Symbol: UNH) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of IWF, in trading today Alphabet Inc (Symbol: GOOG) is up about 1.1%, UnitedHealth Group Inc (Symbol: UNH) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... |
24,158 | 2021-03-31 00:00:00 UTC | The Best Value Stock to Buy Right Now | ABBV | https://www.nasdaq.com/articles/the-best-value-stock-to-buy-right-now-2021-03-31 | null | null | Investors who are bargain hunters are having to look pretty hard right now to find stocks trading at a discount. That's not surprising, with a stock market that has tripled in value over the past 10 years.
But while they're few and far between, bargains still can be found. There's one stock, in particular, that I think... | AbbVie had hoped to win FDA approval for JAK inhibitor Rinvoq in treating psoriatic arthritis by now. However, the FDA pushed its decision back three months and requested additional information from AbbVie about the benefit-risk profile for the drug. In my opinion, the best value stock to buy right now is AbbVie (NYSE:... | In my opinion, the best value stock to buy right now is AbbVie (NYSE: ABBV). AbbVie ranks as the biggest of the group. However, most of them are small-cap stocks that don't come close to measuring up to AbbVie in terms of overall strength. | Playing devil's advocate My view is that AbbVie appears to be a great stock to buy for many investors. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of... | The autoimmune-disease drug contributed more than 43% of AbbVie's total revenue last year. Despite these risks, AbbVie still ranks as the best value stock on the market, in my view. In my opinion, the best value stock to buy right now is AbbVie (NYSE: ABBV). |
24,159 | 2021-03-30 00:00:00 UTC | 7 Cannabis Stocks That Offer Much More Than Just Pot | ABBV | https://www.nasdaq.com/articles/7-cannabis-stocks-that-offer-much-more-than-just-pot-2021-03-30 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
During the Trump administration, one commodity strangely sparked consensus in what was otherwise a tumultuous period. That’s right, I’m talking about cannabis! With landmark legislation such as the Agriculture Improvement Act of 2018, colloquially known as ... | A few years ago, green-friendly investors added ABBV stock to their portfolio on the basis of Marinol, a cannabinoid indicated in adults for anorexia and associated with weight loss in patients with AIDS. Some of these names include the following: Scotts Miracle-Gro (NYSE:SMG) AbbVie (NYSE:ABBV) Pfizer (NYSE:PFE) Const... | Some of these names include the following: Scotts Miracle-Gro (NYSE:SMG) AbbVie (NYSE:ABBV) Pfizer (NYSE:PFE) Constellation Brands (NYSE:STZ) cbdMD (NYSEAMERICAN:YCBD) Innovative Industrial Properties (NYSE:IIPR) Village Farms (NASDAQ:VFF) Lastly, the market is turning quite volatile recently. AbbVie (ABBV) Another com... | Some of these names include the following: Scotts Miracle-Gro (NYSE:SMG) AbbVie (NYSE:ABBV) Pfizer (NYSE:PFE) Constellation Brands (NYSE:STZ) cbdMD (NYSEAMERICAN:YCBD) Innovative Industrial Properties (NYSE:IIPR) Village Farms (NASDAQ:VFF) Lastly, the market is turning quite volatile recently. AbbVie (ABBV) Another com... | Plus, as a diversified opportunity, I especially like ABBV stock for the underlying company’s acquisition of Botox. This is one that surprised me, but Pfizer currently has “25 U.S. patents for molecules relating to the cannabis plant.” As with big pharmaceutical rival AbbVie, Pfizer apparently sees significant value in... |
24,160 | 2021-03-29 00:00:00 UTC | This Stalwart's Growth Story Isn't Over Yet | ABBV | https://www.nasdaq.com/articles/this-stalwarts-growth-story-isnt-over-yet-2021-03-29 | null | null | Pharmaceutical stocks have lagged the broader market recently, with the Vanguard Health Care Fund ETF (NYSEMKT: VHT) trailing the S&P 500 by about 15% in the past year and 10% in the past five. And while a majority of big-pharma names (like Pfizer, Bristol Myers Squibb, and AbbVie) continue to underperform, Eli Lilly (... | And while a majority of big-pharma names (like Pfizer, Bristol Myers Squibb, and AbbVie) continue to underperform, Eli Lilly (NYSE: LLY) is an exception. One of the world's largest pharmaceutical companies, Eli Lilly is poised to keep going higher, deploying its resources to tackle some of the biggest health challenges... | And while a majority of big-pharma names (like Pfizer, Bristol Myers Squibb, and AbbVie) continue to underperform, Eli Lilly (NYSE: LLY) is an exception. The company's wide range of products treats conditions including cancer, diabetes, immune disorders, and more. The Motley Fool recommends Johnson & Johnson. | And while a majority of big-pharma names (like Pfizer, Bristol Myers Squibb, and AbbVie) continue to underperform, Eli Lilly (NYSE: LLY) is an exception. It's beaten the market for years, and it's not stopping now Eli Lilly is one of the few pharmaceutical companies that has managed to outperform the S&P 500 over the p... | And while a majority of big-pharma names (like Pfizer, Bristol Myers Squibb, and AbbVie) continue to underperform, Eli Lilly (NYSE: LLY) is an exception. In 2019 alone, Trulicity did $4.1 billion in sales, and that number increased by almost 20% in fiscal 2020, to $5.06 billion. The bottom line is that the growth is no... |
24,161 | 2021-03-28 00:00:00 UTC | 3 High-Yield Dividend Stocks With Solid Growth Prospects | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-with-solid-growth-prospects-2021-03-28 | null | null | Trade-offs are inevitable when it comes to investing. The biggest one is the relationship between risk and returns. If you want lower risk, you'll usually have to forego the possibility of big returns.
However, some investing trade-offs aren't unavoidable. For example, you don't necessarily have to give up on the poten... | AbbVie You're not going to find many stocks with the dividend pedigree that AbbVie (NYSE: ABBV) has. AbbVie is a Dividend Aristocrat with 49 consecutive years of dividend increases. AbbVie's revenue soared 59% year over year in the fourth quarter of 2020 with adjusted earnings per share (EPS) jumping 32%. | AbbVie's revenue soared 59% year over year in the fourth quarter of 2020 with adjusted earnings per share (EPS) jumping 32%. AbbVie You're not going to find many stocks with the dividend pedigree that AbbVie (NYSE: ABBV) has. AbbVie is a Dividend Aristocrat with 49 consecutive years of dividend increases. | AbbVie is a Dividend Aristocrat with 49 consecutive years of dividend increases. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, and Pfizer. AbbVie You're not going to find many stocks with the dividend pedigree that AbbVie (NYSE: ABBV... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, and Pfizer. AbbVie You're not going to find many stocks with the dividend pedigree that AbbVie (NYSE: ABBV) has. AbbVie is a Dividend Aristocrat with 49 consecutive years of dividend incr... |
24,162 | 2021-03-23 00:00:00 UTC | Merck Stock Remains Significantly Undervalued At $77 | ABBV | https://www.nasdaq.com/articles/merck-stock-remains-significantly-undervalued-at-%2477-2021-03-23 | null | null | Merck (NYSE: MRK) looks very attractive at current levels of $77, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks a significant underperformance compared to the S&P which has moved 75% since its March 2020 lows, with the resu... | This marks a significant underperformance compared to the S&P which has moved 75% since its March 2020 lows, with the resumption of economic activities as lockdowns are gradually lifted and vaccination programs have been initiated in multiple countries. Though the Covid-19 pandemic surely impacted the sales growth for ... | For Merck much of the revenue growth over the recent years has been led by its oncology drug – Keytruda – which saw its sales double from $7.1 billion in 2017 to $14.4 billion in 2020. Looking at valuation, at the current price of $77, Merck is trading at 12x its estimated adjusted EPS of around $6.56 in 2021, compared... | Merck (NYSE: MRK) looks very attractive at current levels of $77, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. For Merck much of the revenue growth over the recent years has been led by its oncology drug – Keytruda – which saw its sa... | For Merck much of the revenue growth over the recent years has been led by its oncology drug – Keytruda – which saw its sales double from $7.1 billion in 2017 to $14.4 billion in 2020. Looking at valuation, at the current price of $77, Merck is trading at 12x its estimated adjusted EPS of around $6.56 in 2021, compared... |
24,163 | 2021-03-22 00:00:00 UTC | First Week of ABBV August 20th Options Trading | ABBV | https://www.nasdaq.com/articles/first-week-of-abbv-august-20th-options-trading-2021-03-22 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the August 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 151 days until expiration the newly trading contracts represent a potential opportunity for sellers... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $160.00 strike highlighted in red: Considering the fact that the $160.00 strike represents an approximate 53% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the po... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $100.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $160.00 strike price has a current bid of 9 cents. Below is a chart showing A... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new August 20th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $160.00 strike highlighted in red: Conside... |
24,164 | 2021-03-21 00:00:00 UTC | 3 Embarrassingly Cheap Dividend Stocks | ABBV | https://www.nasdaq.com/articles/3-embarrassingly-cheap-dividend-stocks-2021-03-21 | null | null | You'd think that investors would be willing to pay more for stocks that pay them back every quarter with a juicy dividend. However, that's not always the case.
There are plenty of dividend stocks with valuations that are attractive. And some of them are really inexpensive. Here are three dividend stocks that are almost... | AbbVie AbbVie (NYSE: ABBV) arguably ranks as one of the best dividend stocks on the market. AbbVie's shares trade at close to 8.5 times expected earnings. Why is AbbVie valued so attractively? | Bristol Myers Squibb Like AbbVie, Bristol Myers Squibb (NYSE: BMY) is one of the dirt cheap big pharma stocks that Warren Buffett really likes these days. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie (... | Bristol Myers Squibb Like AbbVie, Bristol Myers Squibb (NYSE: BMY) is one of the dirt cheap big pharma stocks that Warren Buffett really likes these days. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie (... | AbbVie's shares trade at close to 8.5 times expected earnings. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie (NYSE: ABBV) arguably ranks as one of the best dividend stocks on the market. |
24,165 | 2021-03-19 00:00:00 UTC | iShares Core S&P 500 ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-sp-500-etf-experiences-big-inflow-2021-03-19 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $648.4 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 653,500,000 to 6... | Among the largest underlying components of IVV, in trading today Coca-Cola Co (Symbol: KO) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.5%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IVV, in trading today Coca-Cola Co (Symbol: KO) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.5%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IVV, in trading today Coca-Cola Co (Symbol: KO) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of IVV, in trading today Coca-Cola Co (Symbol: KO) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
24,166 | 2021-03-19 00:00:00 UTC | 1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should | ABBV | https://www.nasdaq.com/articles/1-stock-warren-buffett-and-cathie-wood-have-in-common-and-1-they-should-2021-03-19 | null | null | It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about "overvalued" stocks -- would have the same company in their portfolios. P... | In the third quarter of 2020 he added shares of Pfizer (NYSE: PFE), AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Bristol Myers Squibb (NYSE: BMY). Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to... | In the third quarter of 2020 he added shares of Pfizer (NYSE: PFE), AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Bristol Myers Squibb (NYSE: BMY). In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stock Berkshire Hathaway (NYSE: BRK.A)(NYS... | In the third quarter of 2020 he added shares of Pfizer (NYSE: PFE), AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Bristol Myers Squibb (NYSE: BMY). In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stock Berkshire Hathaway (NYSE: BRK.A)(NYS... | In the third quarter of 2020 he added shares of Pfizer (NYSE: PFE), AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Bristol Myers Squibb (NYSE: BMY). The surprising stock they both own First, it's doubtful that Warren Buffett actually bought Snowflake (NYSE: SNOW), the cloud data warehouse-as-a-service company. It turns ou... |
24,167 | 2021-03-18 00:00:00 UTC | Analysts See 10% Gains Ahead For The Holdings of DEF | ABBV | https://www.nasdaq.com/articles/analysts-see-10-gains-ahead-for-the-holdings-of-def-2021-03-18 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Defensive Equity ETF (S... | Invesco Defensive Equity ETF DEF $59.73 $65.49 9.64% Procter & Gamble Company PG $128.42 $151.00 17.58% Dominion Energy Inc D $73.17 $81.36 11.20% AbbVie Inc ABBV $105.04 $116.73 11.13% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DE... | Three of DEF's underlying holdings with notable upside to their analyst target prices are Procter & Gamble Company (Symbol: PG), Dominion Energy Inc (Symbol: D), and AbbVie Inc (Symbol: ABBV). Similarly, D has 11.20% upside from the recent share price of $73.17 if the average analyst target price of $81.36/share is rea... | Similarly, D has 11.20% upside from the recent share price of $73.17 if the average analyst target price of $81.36/share is reached, and analysts on average are expecting ABBV to reach a target price of $116.73/share, which is 11.13% above the recent price of $105.04. Three of DEF's underlying holdings with notable ups... | Invesco Defensive Equity ETF DEF $59.73 $65.49 9.64% Procter & Gamble Company PG $128.42 $151.00 17.58% Dominion Energy Inc D $73.17 $81.36 11.20% AbbVie Inc ABBV $105.04 $116.73 11.13% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DE... |
24,168 | 2021-03-17 00:00:00 UTC | 4 Top Stock Trades for Thursday: ABBV, TLT, PDD, FIVE | ABBV | https://www.nasdaq.com/articles/4-top-stock-trades-for-thursday%3A-abbv-tlt-pdd-five-2021-03-17 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We’re getting the typical volatility associated with a Fed Day, as stocks gyrate around the Federal Reserve’s commentary and asset-buying plans. So far, the reaction has been bullish, but we’ll need to see how we finish the week. That said, let’s look at so... | Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) stock has been a solid performer from the fourth-quarter lows, ripping from about $80 to more than $100 by the end of the year. 1: AbbVie (ABBV) If ABBV stock loses Wednesday’s low, look for support at the 200-day moving average and the prior 202... | Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) stock has been a solid performer from the fourth-quarter lows, ripping from about $80 to more than $100 by the end of the year. 1: AbbVie (ABBV) If ABBV stock loses Wednesday’s low, look for support at the 200-day moving average and the prior 202... | If ABBV stock loses Wednesday’s low, look for support at the 200-day moving average and the prior 2020 pre-coronavirus high near $98. 1: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) stock has been a solid performer from the fourth-quarter lows, ripping from about $80 to more t... | The post 4 Top Stock Trades for Thursday: ABBV, TLT, PDD, FIVE appeared first on InvestorPlace. 1: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) stock has been a solid performer from the fourth-quarter lows, ripping from about $80 to more than $100 by the end of the year. |
24,169 | 2021-03-17 00:00:00 UTC | S&P 500 Movers: NRG, DOW | ABBV | https://www.nasdaq.com/articles/sp-500-movers%3A-nrg-dow-2021-03-17 | null | null | In early trading on Wednesday, shares of Dow topped the list of the day's best performing components of the S&P 500 index, trading up 3.6%. Year to date, Dow registers a 17.9% gain.
And the worst performing S&P 500 component thus far on the day is NRG Energy, trading down 13.8%. NRG Energy Inc is lower by about 0.3% lo... | Two other components making moves today are AbbVie, trading down 6.4%, and Host Hotels & Resorts, trading up 2.8% on the day. And the worst performing S&P 500 component thus far on the day is NRG Energy, trading down 13.8%. NRG Energy Inc is lower by about 0.3% looking at the year to date performance. | Two other components making moves today are AbbVie, trading down 6.4%, and Host Hotels & Resorts, trading up 2.8% on the day. In early trading on Wednesday, shares of Dow topped the list of the day's best performing components of the S&P 500 index, trading up 3.6%. And the worst performing S&P 500 component thus far on... | Two other components making moves today are AbbVie, trading down 6.4%, and Host Hotels & Resorts, trading up 2.8% on the day. In early trading on Wednesday, shares of Dow topped the list of the day's best performing components of the S&P 500 index, trading up 3.6%. And the worst performing S&P 500 component thus far on... | Two other components making moves today are AbbVie, trading down 6.4%, and Host Hotels & Resorts, trading up 2.8% on the day. And the worst performing S&P 500 component thus far on the day is NRG Energy, trading down 13.8%. NRG Energy Inc is lower by about 0.3% looking at the year to date performance. |
24,170 | 2021-03-17 00:00:00 UTC | U.S. FDA extends review period for expanded use of Abbvie's arthritis drug | ABBV | https://www.nasdaq.com/articles/u.s.-fda-extends-review-period-for-expanded-use-of-abbvies-arthritis-drug-2021-03-17-0 | null | null | Corrects typo in paragraph 1
March 17 - Abbvie Inc ABBV.N said the U.S. Food and Drug Administration has extended the review period for expanded use of its rheumatoid arthritis drug Rinvoq by three months, citing the need for more time to assess the drug's benefit-risk profile.
Shares of the drugmaker fell 7.04% to $10... | Abbvie has been betting on Rinvoq as it is set to lose patent protection in 2023 for its blockbuster drug Humira in the United States, its biggest market. FDA is also reviewing the expanded use of Rinvoq in atopic dermatitis and has sought additional information, which Abbvie plans to provide shortly. Corrects typo in ... | Corrects typo in paragraph 1 March 17 - Abbvie Inc ABBV.N said the U.S. Food and Drug Administration has extended the review period for expanded use of its rheumatoid arthritis drug Rinvoq by three months, citing the need for more time to assess the drug's benefit-risk profile. Abbvie said on Wednesday the U.S. health ... | Corrects typo in paragraph 1 March 17 - Abbvie Inc ABBV.N said the U.S. Food and Drug Administration has extended the review period for expanded use of its rheumatoid arthritis drug Rinvoq by three months, citing the need for more time to assess the drug's benefit-risk profile. Abbvie said on Wednesday the U.S. health ... | Corrects typo in paragraph 1 March 17 - Abbvie Inc ABBV.N said the U.S. Food and Drug Administration has extended the review period for expanded use of its rheumatoid arthritis drug Rinvoq by three months, citing the need for more time to assess the drug's benefit-risk profile. Abbvie said on Wednesday the U.S. health ... |
24,171 | 2021-03-17 00:00:00 UTC | U.S. FDA extends review period for expanded use of Abbvie's arthritis drug | ABBV | https://www.nasdaq.com/articles/u.s.-fda-extends-review-period-for-expanded-use-of-abbvies-arthritis-drug-2021-03-17 | null | null | March 17 - The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc's ABBV. rheumatoid arthritis drug Rinvoq by three months, the U.S. drugmaker said on Wednesday.
Abbvie said the U.S. health agency is reviewing the application for the use of Rinvoq in patients with active pso... | March 17 - The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc's ABBV. Abbvie said the U.S. health agency is reviewing the application for the use of Rinvoq in patients with active psoriatic arthritis. (Reporting by Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel)... | March 17 - The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc's ABBV. Abbvie said the U.S. health agency is reviewing the application for the use of Rinvoq in patients with active psoriatic arthritis. rheumatoid arthritis drug Rinvoq by three months, the U.S. drugmaker s... | Abbvie said the U.S. health agency is reviewing the application for the use of Rinvoq in patients with active psoriatic arthritis. March 17 - The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc's ABBV. rheumatoid arthritis drug Rinvoq by three months, the U.S. drugmaker s... | March 17 - The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc's ABBV. Abbvie said the U.S. health agency is reviewing the application for the use of Rinvoq in patients with active psoriatic arthritis. rheumatoid arthritis drug Rinvoq by three months, the U.S. drugmaker s... |
24,172 | 2021-03-17 00:00:00 UTC | 4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package | ABBV | https://www.nasdaq.com/articles/4-pharma-stocks-that-could-be-losers-with-the-%241.9-trillion-stimulus-package-2021-03-17 | null | null | Major government spending bills tend to create both winners and losers. The $1.9 trillion stimulus bill recently passed by Congress and signed into law by President Joe Biden is no exception. In this Motley Fool Live video, recorded on March 10, Fool.com contributors Keith Speights and Brian Orelli discuss four pharma ... | Let me ask this though, Brian, how bad do you think the impact will be on these particular stocks; Eli Lilly, AbbVie, Merck, and Jazz Pharmaceuticals? 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believ... | Let me ask this though, Brian, how bad do you think the impact will be on these particular stocks; Eli Lilly, AbbVie, Merck, and Jazz Pharmaceuticals? 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believ... | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie (NYSE: ABBV) with Humira, again rheumatoid arthritis,... | Let me ask this though, Brian, how bad do you think the impact will be on these particular stocks; Eli Lilly, AbbVie, Merck, and Jazz Pharmaceuticals? 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believ... |
24,173 | 2021-03-16 00:00:00 UTC | 3 Reasons to Avoid Arena Pharmaceuticals -- and 1 Reason to Buy | ABBV | https://www.nasdaq.com/articles/3-reasons-to-avoid-arena-pharmaceuticals-and-1-reason-to-buy-2021-03-16 | null | null | What do drugs for weight loss, pulmonary hypertension, and irritable bowel syndrome all have in common? Not much -- except they are all offerings in which Arena Pharmaceuticals (NASDAQ: ARNA) has come close to the finish line over the past two decades, only to come up short.
IMAGE SOURCE: GETTY IMAGES.
Reason No. 1 Not... | The moderate to severe UC market is currently dominated by several blockbuster injectable drugs, including AbbVie's (NYSE: ABBV) Humira, Johnson & Johnson's (NYSE: JNJ) Stelara, and Takeda's (NYSE: TAK) Entyvio. 1 Not to Buy: Approval does not guarantee sales Ten-plus years ago, Arena was touting its appetite-reduction... | The moderate to severe UC market is currently dominated by several blockbuster injectable drugs, including AbbVie's (NYSE: ABBV) Humira, Johnson & Johnson's (NYSE: JNJ) Stelara, and Takeda's (NYSE: TAK) Entyvio. Five years ago, Arena was working on a drug called ralinepag for pulmonary hypertension. Celgene, now a part... | The moderate to severe UC market is currently dominated by several blockbuster injectable drugs, including AbbVie's (NYSE: ABBV) Humira, Johnson & Johnson's (NYSE: JNJ) Stelara, and Takeda's (NYSE: TAK) Entyvio. For a company like Arena, having multiple shots on goal is OK if they are within a certain specialty or drug... | The moderate to severe UC market is currently dominated by several blockbuster injectable drugs, including AbbVie's (NYSE: ABBV) Humira, Johnson & Johnson's (NYSE: JNJ) Stelara, and Takeda's (NYSE: TAK) Entyvio. Clearly this is a lucrative market with room for multiple drugs to be highly successful; the difference is t... |
24,174 | 2021-03-16 00:00:00 UTC | 3 Stocks That'll Turn Your $1,400 Stimulus Check Into a Money Machine | ABBV | https://www.nasdaq.com/articles/3-stocks-thatll-turn-your-%241400-stimulus-check-into-a-money-machine-2021-03-16 | null | null | Uncle Sam wants you...to have more money. Last week, the $1.9 trillion stimulus package was signed into law. Most Americans will soon receive $1,400 stimulus checks.
The best thing to do with the extra cash coming your way is to pay any outstanding bills and make sure you have a solid emergency fund. If you've checked ... | AbbVie AbbVie (NYSE: ABBV) is a big drugmaker that pays a dividend yielding over 4.7%. Even better, AbbVie is a Dividend Aristocrat with an impressive track record of 49 consecutive years of dividend increases. The two successful investors no doubt like AbbVie's dividend, but they probably chose to buy AbbVie just as m... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Enterprise Products Partners. AbbVie AbbVie (NYSE: ABBV) is a big drugmaker that pays a dividend yielding over 4.7%. Even better, AbbVie is a Dividend Aristocrat with an impress... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Enterprise Products Partners. AbbVie AbbVie (NYSE: ABBV) is a big drugmaker that pays a dividend yielding over 4.7%. Even better, AbbVie is a Dividend Aristocrat with an impress... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Enterprise Products Partners. AbbVie AbbVie (NYSE: ABBV) is a big drugmaker that pays a dividend yielding over 4.7%. Even better, AbbVie is a Dividend Aristocrat with an impress... |
24,175 | 2021-03-15 00:00:00 UTC | EXCLUSIVE-AbbVie in talks to sell $5 bln women's drugs portfolio -sources | ABBV | https://www.nasdaq.com/articles/exclusive-abbvie-in-talks-to-sell-%245-bln-womens-drugs-portfolio-sources-2021-03-15-0 | null | null | By Pamela Barbaglia and Arno Schuetze
March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is in discussions to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters.
The move revives a process... | The move revives a process to sell the business, which makes the Lo Loestrin Fe birth control pill, that Allergan started in 2018 only to ditch five months before being acquired by AbbVie in 2019. AbbVie is working with investment bank Morgan Stanley MS.N on an auction process that has attracted interest from private e... | By Pamela Barbaglia and Arno Schuetze March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is in discussions to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters. The move revives a process... | By Pamela Barbaglia and Arno Schuetze March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is in discussions to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters. AbbVie is working with inv... | By Pamela Barbaglia and Arno Schuetze March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is in discussions to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters. The move revives a process... |
24,176 | 2021-03-15 00:00:00 UTC | EXCLUSIVE-AbbVie in talks to sell $5 bln women's drugs portfolio - sources | ABBV | https://www.nasdaq.com/articles/exclusive-abbvie-in-talks-to-sell-%245-bln-womens-drugs-portfolio-sources-2021-03-15 | null | null | By Pamela Barbaglia and Arno Schuetze
March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is holding talks to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters.
The move revives a process ... | The move revives a process to sell the business, which makes Lo Loestrin Fe birth control pill, that Allergan started in 2018 only to ditch five months before being acquired by AbbVie in 2019. AbbVie is working with investment bank Morgan Stanley MS.N on an auction process that has attracted interest from private equit... | By Pamela Barbaglia and Arno Schuetze March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is holding talks to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters. The move revives a process ... | By Pamela Barbaglia and Arno Schuetze March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is holding talks to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters. AbbVie is working with inve... | By Pamela Barbaglia and Arno Schuetze March 15 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N is holding talks to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters. The move revives a process ... |
24,177 | 2021-03-15 00:00:00 UTC | Notable Monday Option Activity: ABBV, U, GRWG | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-abbv-u-grwg-2021-03-15 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 31,929 contracts have traded so far, representing approximately 3.2 million underlying shares. That amounts to about 49.2% of ABBV's average daily trading volume over ... | Especially high volume was seen for the $115 strike call option expiring April 16, 2021, with 3,255 contracts trading so far today, representing approximately 325,500 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbo... | Below is a chart showing ABBV's trailing twelve month trading history, with the $115 strike highlighted in orange: Unity Software Inc (Symbol: U) saw options trading volume of 28,247 contracts, representing approximately 2.8 million underlying shares or approximately 48.7% of U's average daily trading volume over the p... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 31,929 contracts have traded so far, representing approximately 3.2 million underlying shares. Below is a chart showing ABBV's trailing twelve month trading history, w... | Below is a chart showing ABBV's trailing twelve month trading history, with the $115 strike highlighted in orange: Unity Software Inc (Symbol: U) saw options trading volume of 28,247 contracts, representing approximately 2.8 million underlying shares or approximately 48.7% of U's average daily trading volume over the p... |
24,178 | 2021-03-14 00:00:00 UTC | 3 High-Yield Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-buy-now-2021-03-14 | null | null | Any time is a great time to buy solid dividend stocks. The trick, of course, is figuring out which companies' payouts will be steady and reliable.
To aid you in your search for such stocks, here's a trio of companies that have strong underlying businesses and high-yielding dividends that should keep growing for a long ... | AbbVie If you're looking for steadily increasing dividends, AbbVie (NYSE: ABBV) should definitely be on your list. Some investors might be leery of AbbVie because the company's top-selling product, Humira, will lose patent protection in the U.S. in 2023. But will a rapid decline of that drug's sales once generic versio... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, Pfizer, and Viatris Inc. AbbVie If you're looking for steadily increasing dividends, AbbVie (NYSE: ABBV) should definitely be on your list. Some investors might be leery of AbbVie because... | And while the company isn't a Dividend Aristocrat like AbbVie yet, it has boosted its distribution for 22 years in a row. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, Pfizer, and Viatris Inc. AbbVie If you're looking for steadily in... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, Pfizer, and Viatris Inc. AbbVie If you're looking for steadily increasing dividends, AbbVie (NYSE: ABBV) should definitely be on your list. Some investors might be leery of AbbVie because... |
24,179 | 2021-03-13 00:00:00 UTC | Why the Growth Isn't Over for This Best-in-Breed Biotech Stock | ABBV | https://www.nasdaq.com/articles/why-the-growth-isnt-over-for-this-best-in-breed-biotech-stock-2021-03-13 | null | null | It's been a busy few weeks for the healthcare industry, with Pfizer and BioNTech, Moderna, and Johnson & Johnson hard at work manufacturing and distributing their versions of the COVID vaccine all over the country.
There's one big name, however, that's been out of the headlines. It's true that Amgen (NASDAQ: AMGN) has ... | The space has been hot over the past few years, with companies including Amgen, AbbVie, and Celgene (now part of Bristol-Myers) establishing themselves with blockbuster drugs including Humira (AbbVie's treatment for Crohn's disease and other indications), Revlimid (Celgene's medication for myeloma), and Otezla (Amgen's... | The space has been hot over the past few years, with companies including Amgen, AbbVie, and Celgene (now part of Bristol-Myers) establishing themselves with blockbuster drugs including Humira (AbbVie's treatment for Crohn's disease and other indications), Revlimid (Celgene's medication for myeloma), and Otezla (Amgen's... | The space has been hot over the past few years, with companies including Amgen, AbbVie, and Celgene (now part of Bristol-Myers) establishing themselves with blockbuster drugs including Humira (AbbVie's treatment for Crohn's disease and other indications), Revlimid (Celgene's medication for myeloma), and Otezla (Amgen's... | The space has been hot over the past few years, with companies including Amgen, AbbVie, and Celgene (now part of Bristol-Myers) establishing themselves with blockbuster drugs including Humira (AbbVie's treatment for Crohn's disease and other indications), Revlimid (Celgene's medication for myeloma), and Otezla (Amgen's... |
24,180 | 2021-03-11 00:00:00 UTC | These 3 Value Stocks Are Absurdly Cheap Right Now | ABBV | https://www.nasdaq.com/articles/these-3-value-stocks-are-absurdly-cheap-right-now-2021-03-11 | null | null | Are you looking for some ridiculously cheap stocks to buy? Despite the Dow Jones Industrial Average hanging out around all-time highs, there are still some good deals out there. It isn't always easy finding them, especially since the coronavirus pandemic has crippled many businesses, making their earnings look abysmal ... | Three stocks that are trading with forward P/Es of 10 or less (the current P/E for the S&P 500 is 34) that bargain hunters will want to consider buying today include AbbVie (NYSE: ABBV), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Hewlett Packard Enterprise (NYSE: HPE). AbbVie Healthcare company AbbVie currently trades at... | Three stocks that are trading with forward P/Es of 10 or less (the current P/E for the S&P 500 is 34) that bargain hunters will want to consider buying today include AbbVie (NYSE: ABBV), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Hewlett Packard Enterprise (NYSE: HPE). AbbVie Healthcare company AbbVie currently trades at... | Three stocks that are trading with forward P/Es of 10 or less (the current P/E for the S&P 500 is 34) that bargain hunters will want to consider buying today include AbbVie (NYSE: ABBV), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Hewlett Packard Enterprise (NYSE: HPE). AbbVie Healthcare company AbbVie currently trades at... | Three stocks that are trading with forward P/Es of 10 or less (the current P/E for the S&P 500 is 34) that bargain hunters will want to consider buying today include AbbVie (NYSE: ABBV), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Hewlett Packard Enterprise (NYSE: HPE). AbbVie Healthcare company AbbVie currently trades at... |
24,181 | 2021-03-10 00:00:00 UTC | 3 Healthcare Companies Worth a Look | ABBV | https://www.nasdaq.com/articles/3-healthcare-companies-worth-a-look-2021-03-10 | null | null | On this week's episode of Industry Focus: Wildcard, host Jason Moser and Motley Fool contributor Brian Feroldi take a closer look at three companies in the healthcare space that possess many of the characteristics of investments with the potential to offer patient investors tenfold returns!
To catch full episodes of al... | They also have a number of research partnerships with the likes of Johnson & Johnson, AbbVie, AstraZeneca, Biogen, L'Oreal insights to use their technology on other types of skin diseases like psoriasis, and lupus, and atopic dermatitis, etc. On this week's episode of Industry Focus: Wildcard, host Jason Moser and Motl... | They also have a number of research partnerships with the likes of Johnson & Johnson, AbbVie, AstraZeneca, Biogen, L'Oreal insights to use their technology on other types of skin diseases like psoriasis, and lupus, and atopic dermatitis, etc. On this week's episode of Industry Focus: Wildcard, host Jason Moser and Motl... | They also have a number of research partnerships with the likes of Johnson & Johnson, AbbVie, AstraZeneca, Biogen, L'Oreal insights to use their technology on other types of skin diseases like psoriasis, and lupus, and atopic dermatitis, etc. On this week's episode of Industry Focus: Wildcard, host Jason Moser and Motl... | They also have a number of research partnerships with the likes of Johnson & Johnson, AbbVie, AstraZeneca, Biogen, L'Oreal insights to use their technology on other types of skin diseases like psoriasis, and lupus, and atopic dermatitis, etc. Moser: [laughs] We know listeners love healthcare. Feroldi: It's really hard ... |
24,182 | 2021-03-10 00:00:00 UTC | How to Boost Your Retirement Income When Social Security Only Covers 40% | ABBV | https://www.nasdaq.com/articles/how-to-boost-your-retirement-income-when-social-security-only-covers-40-2021-03-10 | null | null | Only 40%? That's right -- Social Security has been designed to provide roughly 40%, on average, of your preretirement income. So don't assume that it will provide enough cash on which to live somewhat comfortably.
That means most of us need to be saving and investing for retirement in order to supplement our Social Sec... | 7.2% International Business Machines (NYSE: IBM) 5.3% Chevron (NYSE: CVX) 4.9% AbbVie (NYSE: ABBV) 4.9% Verizon Communications (NYSE: VZ) 4.5% Walgreens Boots Alliance (NASDAQ: WBA) 4% Merck (NYSE: MRK) 3.6% Cisco Systems (NASDAQ: CSCO) 3.2% Coca-Cola (NYSE: KO) 3.3% CVS Health (NYSE: CVS) 2.8% Data source: Yahoo! Sele... | 7.2% International Business Machines (NYSE: IBM) 5.3% Chevron (NYSE: CVX) 4.9% AbbVie (NYSE: ABBV) 4.9% Verizon Communications (NYSE: VZ) 4.5% Walgreens Boots Alliance (NASDAQ: WBA) 4% Merck (NYSE: MRK) 3.6% Cisco Systems (NASDAQ: CSCO) 3.2% Coca-Cola (NYSE: KO) 3.3% CVS Health (NYSE: CVS) 2.8% Data source: Yahoo! Sele... | 7.2% International Business Machines (NYSE: IBM) 5.3% Chevron (NYSE: CVX) 4.9% AbbVie (NYSE: ABBV) 4.9% Verizon Communications (NYSE: VZ) 4.5% Walgreens Boots Alliance (NASDAQ: WBA) 4% Merck (NYSE: MRK) 3.6% Cisco Systems (NASDAQ: CSCO) 3.2% Coca-Cola (NYSE: KO) 3.3% CVS Health (NYSE: CVS) 2.8% Data source: Yahoo! Sele... | 7.2% International Business Machines (NYSE: IBM) 5.3% Chevron (NYSE: CVX) 4.9% AbbVie (NYSE: ABBV) 4.9% Verizon Communications (NYSE: VZ) 4.5% Walgreens Boots Alliance (NASDAQ: WBA) 4% Merck (NYSE: MRK) 3.6% Cisco Systems (NASDAQ: CSCO) 3.2% Coca-Cola (NYSE: KO) 3.3% CVS Health (NYSE: CVS) 2.8% Data source: Yahoo! Sele... |
24,183 | 2021-03-09 00:00:00 UTC | IVW, QCOM, ABBV, CMCSA: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ivw-qcom-abbv-cmcsa%3A-large-outflows-detected-at-etf-2021-03-09 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $285.6 million dollar outflow -- that's a 1.0% decrease week over week (from 486,550,000 to 481,900,000). Among... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is up about 4.2%, AbbVie Inc (Symbol: ABBV) is up about 1.9%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is up about 4.2%, AbbVie Inc (Symbol: ABBV) is up about 1.9%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is up about 4.2%, AbbVie Inc (Symbol: ABBV) is up about 1.9%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is up about 4.2%, AbbVie Inc (Symbol: ABBV) is up about 1.9%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perf... |
24,184 | 2021-03-09 00:00:00 UTC | 3 Reasons to Invest in Dividend-Paying Stocks for Retirement | ABBV | https://www.nasdaq.com/articles/3-reasons-to-invest-in-dividend-paying-stocks-for-retirement-2021-03-09 | null | null | Here's something you probably didn't know: The average monthly Social Security retirement benefit was recently just $1,547, or about $18,500 per year. Yes, if you earned an above-average income during your working life, you'll likely collect more than that -- but it still is probably not going to be enough to cover you... | AbbVie 4.9% 18% Hasbro 2.9% 8% PepsiCo 3.1% 8% Starbucks 1.7% 18% Apple 0.7% 10% Visa 0.6% 18% Clorox 2.4% 8% Walgreen Boots Alliance 4% 5% Data sources: Yahoo! See the 10 stocks *Stock Advisor returns as of February 24, 2021 Selena Maranjian owns shares of AbbVie, Apple, and Starbucks. They deliver income through thic... | AbbVie 4.9% 18% Hasbro 2.9% 8% PepsiCo 3.1% 8% Starbucks 1.7% 18% Apple 0.7% 10% Visa 0.6% 18% Clorox 2.4% 8% Walgreen Boots Alliance 4% 5% Data sources: Yahoo! See the 10 stocks *Stock Advisor returns as of February 24, 2021 Selena Maranjian owns shares of AbbVie, Apple, and Starbucks. Here's something you probably di... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Selena Maranjian owns shares of AbbVie, Apple, and Starbucks. AbbVie 4.9% 18% Hasbro 2.9% 8% PepsiCo 3.1% 8% Starbucks 1.7% 18% Apple 0.7% 10% Visa 0.6% 18% Clorox 2.4% 8% Walgreen Boots Alliance 4% 5% Data sources: Yahoo! But if some or many of your stoc... | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Selena Maranjian owns shares of AbbVie, Apple, and Starbucks. AbbVie 4.9% 18% Hasbro 2.9% 8% PepsiCo 3.1% 8% Starbucks 1.7% 18% Apple 0.7% 10% Visa 0.6% 18% Clorox 2.4% 8% Walgreen Boots Alliance 4% 5% Data sources: Yahoo! Here's something you probably di... |
24,185 | 2021-03-07 00:00:00 UTC | 5 High-Yield Dividend Stocks to Buy for a Biden Bull Market | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-buy-for-a-biden-bull-market-2021-03-07 | null | null | Historically, it hasn't mattered whether a Democrat or Republican has been president: Stock market investors do quite well with either party in office, as long as they're focused on the long term.
However, it's hard to ignore the near-perfect scenario that President Joe Biden and his administration have walked into. Al... | AbbVie: 4.8% dividend yield Although healthcare stocks aren't well known for their dividends, diversified drug developer AbbVie (NYSE: ABBV) looks poised to shine with Biden as president. The biggest knock against AbbVie has always been that it's too reliant on the anti-inflammatory drug Humira. Last year, Humira broug... | AbbVie: 4.8% dividend yield Although healthcare stocks aren't well known for their dividends, diversified drug developer AbbVie (NYSE: ABBV) looks poised to shine with Biden as president. The biggest knock against AbbVie has always been that it's too reliant on the anti-inflammatory drug Humira. Last year, Humira broug... | AbbVie: 4.8% dividend yield Although healthcare stocks aren't well known for their dividends, diversified drug developer AbbVie (NYSE: ABBV) looks poised to shine with Biden as president. The biggest knock against AbbVie has always been that it's too reliant on the anti-inflammatory drug Humira. Last year, Humira broug... | AbbVie: 4.8% dividend yield Although healthcare stocks aren't well known for their dividends, diversified drug developer AbbVie (NYSE: ABBV) looks poised to shine with Biden as president. The biggest knock against AbbVie has always been that it's too reliant on the anti-inflammatory drug Humira. Last year, Humira broug... |
24,186 | 2021-03-05 00:00:00 UTC | Notable Friday Option Activity: ABBV, DE, QCOM | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-abbv-de-qcom-2021-03-05 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 29,064 contracts has been traded thus far today, a contract volume which is representative of approximately 2.9 million underlying shares (given that every ... | Particularly high volume was seen for the $110 strike call option expiring May 21, 2021, with 7,779 contracts trading so far today, representing approximately 777,900 underlying shares of ABBV. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (S... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 29,064 contracts has been traded thus far today, a contract volume which is representative of approximately 2.9 million underlying shares (given that every ... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 29,064 contracts has been traded thus far today, a contract volume which is representative of approximately 2.9 million underlying shares (given that every ... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 29,064 contracts has been traded thus far today, a contract volume which is representative of approximately 2.9 million underlying shares (given that every ... |
24,187 | 2021-03-04 00:00:00 UTC | 5 Stocks Warren Buffett Just Sold From Berkshire's Portfolio | ABBV | https://www.nasdaq.com/articles/5-stocks-warren-buffett-just-sold-from-berkshires-portfolio-2021-03-04 | null | null | Warren Buffett has said "our favorite holding period is forever," but this doesn't necessarily mean that Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) will hold any of its stocks forever. In fact, Buffett and his investing team sell stocks regularly, and for a variety of reasons.
In this Fool Live video clip, recorded ... | I mentioned Bristol Myers (NYSE: BMY), AbbVie (NYSE: ABBV), but sold out of Pfizer completely. In fact, Buffett and his investing team sell stocks regularly, and for a variety of reasons. In this Fool Live video clip, recorded on Feb. 22, Fool.com contributor Matt Frankel, CFP, and Industry Focus host Jason Moser talk ... | I mentioned Bristol Myers (NYSE: BMY), AbbVie (NYSE: ABBV), but sold out of Pfizer completely. Matthew Frankel, CFP owns shares of Bank of America and Berkshire Hathaway (B shares). The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and Bristol Myers Squibb. | I mentioned Bristol Myers (NYSE: BMY), AbbVie (NYSE: ABBV), but sold out of Pfizer completely. Warren Buffett has said "our favorite holding period is forever," but this doesn't necessarily mean that Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) will hold any of its stocks forever. In this Fool Live video clip, recorde... | I mentioned Bristol Myers (NYSE: BMY), AbbVie (NYSE: ABBV), but sold out of Pfizer completely. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. Frankel: I don't think so. |
24,188 | 2021-03-03 00:00:00 UTC | 7 Great Dividend Stocks Outside the Energy Sector | ABBV | https://www.nasdaq.com/articles/7-great-dividend-stocks-outside-the-energy-sector-2021-03-03 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Last year was a tale of two halves for dividend stocks. The novel coronavirus pandemic made the first half of 2020 a period of payout cuts and halts by S&P 500 Index names, but payouts came back mightily in the second half of the year, indicating that many ... | AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Fortress Transportation & Infrastructure (NYSE:FTAI) Albemarle (NYSE:ACRE) Phillip Morris International (NYSE:PM) Archer-Daniels-Midland (NYSE:ADM) Gaming and Leisure Properties (NASDAQ:GLPI) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is a pharmaceu... | AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Fortress Transportation & Infrastructure (NYSE:FTAI) Albemarle (NYSE:ACRE) Phillip Morris International (NYSE:PM) Archer-Daniels-Midland (NYSE:ADM) Gaming and Leisure Properties (NASDAQ:GLPI) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is a pharmaceu... | AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Fortress Transportation & Infrastructure (NYSE:FTAI) Albemarle (NYSE:ACRE) Phillip Morris International (NYSE:PM) Archer-Daniels-Midland (NYSE:ADM) Gaming and Leisure Properties (NASDAQ:GLPI) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is a pharmaceu... | AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Fortress Transportation & Infrastructure (NYSE:FTAI) Albemarle (NYSE:ACRE) Phillip Morris International (NYSE:PM) Archer-Daniels-Midland (NYSE:ADM) Gaming and Leisure Properties (NASDAQ:GLPI) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is a pharmaceu... |
24,189 | 2021-03-02 00:00:00 UTC | 6 Things to Do When the Stock Market Skyrockets | ABBV | https://www.nasdaq.com/articles/6-things-to-do-when-the-stock-market-skyrockets-2021-03-02 | null | null | When the stock market has a great day, it's supposed to be good news. That's what happened on Mar. 1, when markets like the S&P 500 posted some of their best point gains in history. But let's face it: Sometimes, it leaves you feeling like you've missed out on the chance to score a bargain.
Fear not, though: Whether the... | He used the freed-up cash to diversify with stocks like AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ). Copy Warren Buffett's strategy When you own a stock that's already soared, it can become too highly concentrated in your portfolio. Instead of cashing out, copy Buffett's strategy for dealing with winners:... | He used the freed-up cash to diversify with stocks like AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ). Throughout 2020, Buffett modestly cut Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) share in Apple (NASDAQ: AAPL). The Motley Fool owns shares of and recommends Amazon, Apple, and Berkshire Hathaway (B ... | He used the freed-up cash to diversify with stocks like AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ). Buy call options if you're afraid of missing out on gains If you aren't quite ready to buy certain stocks but you think the market will continue to skyrocket, buying call options can help you lock in a low... | He used the freed-up cash to diversify with stocks like AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ). Here's what to do whenever the stock market skyrockets. Buy call options if you're afraid of missing out on gains If you aren't quite ready to buy certain stocks but you think the market will continue to s... |
24,190 | 2021-03-02 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-2021-03-02 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Medtronic PLC (Symbol: MDT) $117.86 $128.21 8.78% National Fuel Gas Co. (Symbol: NFG) $45.88 $49.83 8.62% AbbVie Inc (Symbol: ABBV) $108.41 $116.73 7.68% Brown & Brown Inc (Symbol: BRO) $46.84 $50.00 6.75% UGI Corp. (Symbol: UGI) $38.54 $40.50 5.09% The average 12-month analyst targets are only targets for the share pr... | Medtronic PLC (Symbol: MDT) $117.86 $128.21 8.78% National Fuel Gas Co. (Symbol: NFG) $45.88 $49.83 8.62% AbbVie Inc (Symbol: ABBV) $108.41 $116.73 7.68% Brown & Brown Inc (Symbol: BRO) $46.84 $50.00 6.75% UGI Corp. (Symbol: UGI) $38.54 $40.50 5.09% The average 12-month analyst targets are only targets for the share pr... | Medtronic PLC (Symbol: MDT) $117.86 $128.21 8.78% National Fuel Gas Co. (Symbol: NFG) $45.88 $49.83 8.62% AbbVie Inc (Symbol: ABBV) $108.41 $116.73 7.68% Brown & Brown Inc (Symbol: BRO) $46.84 $50.00 6.75% UGI Corp. (Symbol: UGI) $38.54 $40.50 5.09% The average 12-month analyst targets are only targets for the share pr... | Medtronic PLC (Symbol: MDT) $117.86 $128.21 8.78% National Fuel Gas Co. (Symbol: NFG) $45.88 $49.83 8.62% AbbVie Inc (Symbol: ABBV) $108.41 $116.73 7.68% Brown & Brown Inc (Symbol: BRO) $46.84 $50.00 6.75% UGI Corp. (Symbol: UGI) $38.54 $40.50 5.09% The average 12-month analyst targets are only targets for the share pr... |
24,191 | 2021-03-02 00:00:00 UTC | Where Will Pfizer Be in 1 Year? | ABBV | https://www.nasdaq.com/articles/where-will-pfizer-be-in-1-year-2021-03-02 | null | null | Those following the headlines about Pfizer (NYSE: PFE) last year may have thought 2020 was all about developing a vaccine for COVID-19. For society at large, it was. For the company, though, 2020 was about transformation. Management is hoping to reestablish Pfizer as a scientific trailblazer after shedding slow-growth ... | Competing drugs like Abbvie's (NYSE: ABBV) Humira, which generated nearly $20 billion in sales last year, and Amgen's (NASDAQ: AMGN) Enbrel, which produced $1.3 billion, take a different approach to treating inflammatory diseases. In oncology, a clinical trial studying the ability of Ibrance to prevent recurrence in wo... | Competing drugs like Abbvie's (NYSE: ABBV) Humira, which generated nearly $20 billion in sales last year, and Amgen's (NASDAQ: AMGN) Enbrel, which produced $1.3 billion, take a different approach to treating inflammatory diseases. Internal medicine $9 billion 22% 3% Oncology $10.9 billion 26% 21% Hospital $8 billion 19... | Competing drugs like Abbvie's (NYSE: ABBV) Humira, which generated nearly $20 billion in sales last year, and Amgen's (NASDAQ: AMGN) Enbrel, which produced $1.3 billion, take a different approach to treating inflammatory diseases. Internal medicine $9 billion 22% 3% Oncology $10.9 billion 26% 21% Hospital $8 billion 19... | Competing drugs like Abbvie's (NYSE: ABBV) Humira, which generated nearly $20 billion in sales last year, and Amgen's (NASDAQ: AMGN) Enbrel, which produced $1.3 billion, take a different approach to treating inflammatory diseases. Breast cancer drug Ibrance is the best seller there, and its sales were up 9% year over y... |
24,192 | 2021-03-01 00:00:00 UTC | 7 Safe Stocks You Can Hold Onto Forever | ABBV | https://www.nasdaq.com/articles/7-safe-stocks-you-can-hold-onto-forever-2021-03-01 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The continued rise in the stock market is widening the gap between value and growth investments. Technology, electric vehicles, special purpose acquisition companies (SPACs) and clean energy are just a few segments that have doubled or more. Dividend-income... | In alphabetical order: Apple (NASDAQ:AAPL) AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) Coca-Cola (NYSE:KO) Altria Group (NYSE:MO) PepsiCo (NASDAQ:PEP) Wells Fargo (NYSE:WFC) Overall Stock Score and quality score on stocks to hold forever. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie shares are stuck in a narr... | In alphabetical order: Apple (NASDAQ:AAPL) AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) Coca-Cola (NYSE:KO) Altria Group (NYSE:MO) PepsiCo (NASDAQ:PEP) Wells Fargo (NYSE:WFC) Overall Stock Score and quality score on stocks to hold forever. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie shares are stuck in a narr... | In alphabetical order: Apple (NASDAQ:AAPL) AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) Coca-Cola (NYSE:KO) Altria Group (NYSE:MO) PepsiCo (NASDAQ:PEP) Wells Fargo (NYSE:WFC) Overall Stock Score and quality score on stocks to hold forever. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie shares are stuck in a narr... | In alphabetical order: Apple (NASDAQ:AAPL) AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) Coca-Cola (NYSE:KO) Altria Group (NYSE:MO) PepsiCo (NASDAQ:PEP) Wells Fargo (NYSE:WFC) Overall Stock Score and quality score on stocks to hold forever. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie shares are stuck in a narr... |
24,193 | 2021-03-01 00:00:00 UTC | iShares S&P 500 Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-sp-500-growth-etf-experiences-big-outflow-2021-03-01 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $295.0 million dollar outflow -- that's a 0.9% decrease week over week (from 491,200,000 to 486,550,000). Among... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is up by about 1.3%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the on... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is up by about 1.3%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the on... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is up by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cover... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is up by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cover... |
24,194 | 2021-02-26 00:00:00 UTC | 5 High-Yield Dividend Stocks to Watch | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-2021-02-26 | null | null | Interest rates may be just a tad above record lows, and while that dynamic is somewhat reflected in bond yields at the moment, it isn't so much in dividend yields. Indeed, a handful of stocks are still dishing out surprisingly high dividend payouts despite the somewhat adverse overall economic environment. Investors lo... | AbbVie Dividend yield: 5% Any investor who knows AbbVie (NYSE: ABBV) well knows it's almost synonymous with its flagship product Humira. But AbbVie may not be in the sort of trouble the market suggests it is. While the company opted to not increase its dividend when it normally would have in December -- for the first t... | AbbVie Dividend yield: 5% Any investor who knows AbbVie (NYSE: ABBV) well knows it's almost synonymous with its flagship product Humira. But AbbVie may not be in the sort of trouble the market suggests it is. New York Community Bancorp Dividend yield: 5.9% Sinking interest rates haven't just worked against bond and div... | AbbVie Dividend yield: 5% Any investor who knows AbbVie (NYSE: ABBV) well knows it's almost synonymous with its flagship product Humira. But AbbVie may not be in the sort of trouble the market suggests it is. New York Community Bancorp Dividend yield: 5.9% Sinking interest rates haven't just worked against bond and div... | AbbVie Dividend yield: 5% Any investor who knows AbbVie (NYSE: ABBV) well knows it's almost synonymous with its flagship product Humira. But AbbVie may not be in the sort of trouble the market suggests it is. It's now got $154 billion in debt on its balance sheet, with the DirecTV property accounting for the biggest pi... |
24,195 | 2021-02-24 00:00:00 UTC | FDA Approves AbbVie's Humira For Pediatric Ulcerative Colitis | ABBV | https://www.nasdaq.com/articles/fda-approves-abbvies-humira-for-pediatric-ulcerative-colitis-2021-02-24 | null | null | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved Humira or adalimumab for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older.
The approval was based on results from the pivotal Phase 3 ENVISION I study, which showed that the... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved Humira or adalimumab for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. The approval was based on results from the pivotal Phase 3 ENVISION I study, which showed that the... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved Humira or adalimumab for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. The approval was based on results from the pivotal Phase 3 ENVISION I study, which showed that the... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved Humira or adalimumab for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. The approval was based on results from the pivotal Phase 3 ENVISION I study, which showed that the... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved Humira or adalimumab for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. The approval was based on results from the pivotal Phase 3 ENVISION I study, which showed that the... |
24,196 | 2021-02-24 00:00:00 UTC | How to Invest Like Warren Buffett in 2021 | ABBV | https://www.nasdaq.com/articles/how-to-invest-like-warren-buffett-in-2021-2021-02-24 | null | null | Warren Buffett stands as one of history's most successful investors. His incredible market-beating tenure as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) and the market-beating investment choices he has made during that time have earned him the moniker The Oracle of Omaha, and it's not hard to see why Buffett's... | Verizon (NYSE: VZ) 146,716,496 $8.29 billion Chevron (NYSE: CVX) 48,498,965 $4.65 billion Marsh & McLennan (NYSE: MMC) 4,267,825 $500 million Merck (NYSE: MRK) 6,294,333 $468 million AbbVie (NYSE: ABBV) 4,286,766 $451 million E.W. The conglomerate ended last year having outperformed the S&P 500 index by roughly 2,700,0... | Verizon (NYSE: VZ) 146,716,496 $8.29 billion Chevron (NYSE: CVX) 48,498,965 $4.65 billion Marsh & McLennan (NYSE: MMC) 4,267,825 $500 million Merck (NYSE: MRK) 6,294,333 $468 million AbbVie (NYSE: ABBV) 4,286,766 $451 million E.W. Scripps (NYSE: SSP) 23,076,923 $441 million T-Mobile (NASDAQ: TMUS) 2,824,844 $337 millio... | Verizon (NYSE: VZ) 146,716,496 $8.29 billion Chevron (NYSE: CVX) 48,498,965 $4.65 billion Marsh & McLennan (NYSE: MMC) 4,267,825 $500 million Merck (NYSE: MRK) 6,294,333 $468 million AbbVie (NYSE: ABBV) 4,286,766 $451 million E.W. His incredible market-beating tenure as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK... | Verizon (NYSE: VZ) 146,716,496 $8.29 billion Chevron (NYSE: CVX) 48,498,965 $4.65 billion Marsh & McLennan (NYSE: MMC) 4,267,825 $500 million Merck (NYSE: MRK) 6,294,333 $468 million AbbVie (NYSE: ABBV) 4,286,766 $451 million E.W. Investors can also replicate Buffett's approach by building positions in Berkshire's bigg... |
24,197 | 2021-02-23 00:00:00 UTC | Cathie Wood Couldn't Stop Buying These 3 Stocks for ARK Invest Last Week | ABBV | https://www.nasdaq.com/articles/cathie-wood-couldnt-stop-buying-these-3-stocks-for-ark-invest-last-week-2021-02-23 | null | null | The hottest person in the usually quiet world of exchange-traded funds is Cathie Wood. Her ARK Invest actively managed ETFs have been a pioneering force in the industry, and the fact that they all doubled in price in 2020 was a huge selling point.
Wood is constantly buying and selling stocks for her five main active ET... | AbbVie Finally, AbbVie (NYSE: ABBV) was a big favorite for the ARK Genomic Revolution ETF (NYSEMKT: ARKG). However, AbbVie has a massive pipeline of candidate treatments along with a solid balance sheet for potential acquisitions and strategic partnerships. Wood apparently believes that AbbVie is well-positioned to tak... | AbbVie Finally, AbbVie (NYSE: ABBV) was a big favorite for the ARK Genomic Revolution ETF (NYSEMKT: ARKG). However, AbbVie has a massive pipeline of candidate treatments along with a solid balance sheet for potential acquisitions and strategic partnerships. Wood apparently believes that AbbVie is well-positioned to tak... | AbbVie Finally, AbbVie (NYSE: ABBV) was a big favorite for the ARK Genomic Revolution ETF (NYSEMKT: ARKG). However, AbbVie has a massive pipeline of candidate treatments along with a solid balance sheet for potential acquisitions and strategic partnerships. Wood apparently believes that AbbVie is well-positioned to tak... | AbbVie Finally, AbbVie (NYSE: ABBV) was a big favorite for the ARK Genomic Revolution ETF (NYSEMKT: ARKG). However, AbbVie has a massive pipeline of candidate treatments along with a solid balance sheet for potential acquisitions and strategic partnerships. Wood apparently believes that AbbVie is well-positioned to tak... |
24,198 | 2021-02-23 00:00:00 UTC | 2 Best Pharma Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-best-pharma-stocks-to-buy-right-now-2021-02-23 | null | null | Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. However, investors seem to be ignoring these well-established pharmaceutical players with diversified product portfolios, deep research pipelines, broad geographic presence, robust cash flows, and he... | Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. AbbVie Biopharmaceutical company AbbVie pays a handsome dividend yield of 4.9%, which is much higher than the S&P 500's yield of 1.6%. In fiscal 2020, the drug accounted for 43% of AbbVie's total rev... | Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. AbbVie Biopharmaceutical company AbbVie pays a handsome dividend yield of 4.9%, which is much higher than the S&P 500's yield of 1.6%. In fiscal 2020, the drug accounted for 43% of AbbVie's total rev... | Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. AbbVie Biopharmaceutical company AbbVie pays a handsome dividend yield of 4.9%, which is much higher than the S&P 500's yield of 1.6%. In fiscal 2020, the drug accounted for 43% of AbbVie's total rev... | AbbVie is also studying Skyrizi and Rinvoq in other Humira indications, and expects the two drugs to fetch risk-adjusted sales over $15 billion by 2025. Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. AbbVie Biopharmaceutical company AbbVie pays a... |
24,199 | 2021-02-23 00:00:00 UTC | Warren Buffett Just Bought These 2 Dirt-Cheap Stocks. Should You? | ABBV | https://www.nasdaq.com/articles/warren-buffett-just-bought-these-2-dirt-cheap-stocks.-should-you-2021-02-23 | null | null | We now know which stocks Warren Buffett liked and disliked in the fourth quarter of 2020. Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) submitted its 13F-HR regulatory filing to the U.S. Securities and Exchange Commission (SEC) last week.
In total, Berkshire bought 10 stocks in Q4. Its activity featured new positions ... | Buffett's dirt cheap buys Berkshire first scooped up shares of AbbVie and Bristol Myers Squibb in the third quarter. BMS doesn't have as impressive of a track record as AbbVie does, but I suspect Buffett liked the drugmaker's dividend yield of over 3.2%. Its activity featured new positions in four stocks and adding to ... | Attractive beyond their valuations Buffett likely viewed AbbVie's and Bristol Myers Squibb's valuations as too cheap to pass up. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), Bristol Myers Squibb, and Pfizer. Its activity featured n... | Its activity featured new positions in four stocks and adding to positions in six stocks, including AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), Bristol Myers Squibb, and Pf... | Buffett's dirt cheap buys Berkshire first scooped up shares of AbbVie and Bristol Myers Squibb in the third quarter. The third growth phase, though, should begin in 2025 and beyond as AbbVie returns to strong growth and the company's other products more than offset Humira's declining sales. See the 10 stocks *Stock Adv... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.